

# Quantitative determination and localization of cathepsin D and its inhibitors

Alina Minarowska<sup>1</sup>, Alicja Karwowska<sup>2</sup>, Marek Gacko<sup>3</sup>

<sup>1</sup>Department of Clinical Nursing, Medical University of Białystok

<sup>2</sup>Department of Epidemiology and Hygiene, Medical University of Białystok

<sup>3</sup>Department of Vascular Surgery, Medical University of Białystok

**Abstract:** A literature survey was performed of the methods of quantitative assessment of the activity and concentration of cathepsin D and its inhibitors. Usefulness of non-modified and modified proteins and synthetic peptides as measurement substrates was evaluated. The survey includes also chemical and immunochemical methods used to determine the distribution of cathepsin D and its inhibitors in cells and tissues.

**Key words:** cathepsin D, cathepsin D inhibitors, activity, concentration, cell distribution, tissue distribution

Cathepsin D (EC 3.4.23.5) is a lysosomal aspartyl endopeptidase, localized in all cells and tissues, except for mature erythrocytes [1-3]. Methods used to determine the activity, concentration and cellular distribution of cathepsin D, but not its inhibitors, have previously been the subject of literature reports [4-12]. However, since the time of their publication a number of new substrates and analytical techniques have been implemented.


## Structure, specificity, mechanism of action

Cathepsin D is synthesized in the rough endoplasmic reticulum as procathepsin D, built up of 412 amino acid residues [13-15]. As a result of cleavage of the 20-amino acid signal prepeptide, it is converted into procathepsin D which undergoes glycosylation and disulphide bridges are formed in its molecule. Procathepsin D is transported from cisterns of the rough endoplasmic reticulum to the Golgi apparatus, from which, with the involvement of mannosyl-6-phosphate (M-6-P) receptors, it is transferred to primary lysosomes [16,17]. As the M-6-P receptors are known to occur in

the primary lysosomes but not in the mature ones, they can be used to distinguish between these two types of lysosomes [18]. In the acidic environment of the lysosomes (pH 4.5-5.5), due to autocatalytic cleavage of the 44-amino acid propeptide from the N-terminal molecule, procathepsin D is converted into the active one-chain form. The actions of cysteine proteinase, aminopeptidases and carboxypeptidases lead to the formation of an active two-chain form of cathepsin D (Fig. 1). These chains are bound by hydrophobic bonds. The molecular weight of the ultimate mature form of cathepsin D is 48 (14+34) kDa. The proteolytic activities of the one-chain and two-chain forms are very similar [19,20]. Modification of the polypeptide chain, different oligosaccharide composition types and phosphorylation/dephosphorylation in the amino saccharide residues contribute to marked molecular heterogeneity of cathepsin D and cause differences in isoelectric points of the respective isoenzymes between pH 4.5 – 6.5 [21,22].


The use of peptides with the known primary structure allows identification of amino acid residues that form peptide bonds cleaved by cathepsin D. For this purpose, synthetic peptides [23] and chains A and B of bovine insulin can be used (Fig. 2). Cathepsin D cleaves the peptide bonds found within the polypeptide chain, formed by carboxyl groups of the hydrophobic amino acid residues: aromatic – trypto-

**Correspondence:** A. Minarowska, Dept. of Clinical Nursing, Collegium Novum, Waszyngtona 15A Str., 15-274 Białystok, Poland; tel./fax: (+4885) 7468581, e-mail: minar@mp.pl




**Fig. 1.** Proteolytic modification of procatepsin D. PS – signaling peptide, EP – endopeptidase, AP – aminopeptidase, EPc – cysteinyl endopeptidase, CP – carboxypeptidase,  $\bullet\bullet\bullet$  – hydrophobic bond.


#### Insulin A-Chain



#### Insulin B-Chain



#### Peptide D



**Fig. 2.** Specificity of porcine spleen cathepsin D. The specificity of the enzyme is shown in the sites of cleavage in four peptides; oxidized A chain of bovine insulin, oxidized B chain of bovine insulin, peptide D, and acetylated peptide D. The vertical arrows below the sequences indicate the relative preference of the hydrolyzed site. They are assigned either from the peptide yields or from the carboxypeptidase A digestions [24]. ↑ – high yield sites; ↑ – medium yield sites; ↑ – low yield sites.

phan, tyrosine and phenylalanine, and long-chain aliphatic amino acids – leucine and isoleucine (Fig. 3) [23].

Two aspartic acid residues, *i.e.* Asp33 and Asp231 constitute the catalytic site of cathepsin D. Tyr205 and to a lesser extent other amino acid residues evolve as the third component of the catalytic triad. The course of cathepsin D-catalyzed hydrolysis of the peptide bond is presented in Fig. 4. The hydrolysis starts with two simultaneous proton transfers (reaction a), one between the water molecule and the carboxyl ion Asp33, the other between the carboxyl group of

Asp231 and the oxygen atom of the carboxyl group in the substrate. These transfers facilitate formation of indirect tetrahedral product. An analogous mechanism of double transfer leads to decomposition of the indirect product (reaction b), in which a proton of the hydroxyl group is transferred onto the Asp33, whereas the Asp231 is transported onto the nitrogen atom, and thereby the peptide bond -CO-NH- is hydrolyzed in the substrate. The first product of reaction with the free carboxyl group (R<sub>1</sub>-COOH) and the second product of reaction with the free amino group (R<sub>2</sub>-NH<sub>2</sub>) are generated, and cathepsin D is released (reaction c).




Fig. 3. The Schechter and Berger nomenclature for binding of peptide substrate to cathepsin D. The cathepsin D is represent as the shaded area. P1-P1' are side chains of six amino acids, and S1-S1' are the corresponding subsides on the cathepsin D.




Fig. 4. Hydrolysis of a peptide bond [25].

Cathepsin D cleaves only certain peptide bonds in proteins, and does it in a defined sequence. Rupture of even one peptide bond in a native protein molecule changes its spatial structure. The glomerular structure of native protein is converted into the fibril-like one, thus rendering peptide bonds accessible to cathepsin D and leading to progressing degradation of protein molecule. In this process, the mass concentration of the protein remains stable, whereas the molar concentration increases. Progressing fragmentation, spatial changes in the protein and effects exerted on the peptide fragments of aminopeptidases and carboxypeptidases prolong protein degradation until amino acids are formed.

**The optimum pH and range of cathepsin D activity**

Cathepsin D acts in an acidic pH range (3.0 – 4.5). The optimum pH depends on the type of protein and synthetic peptide [26,27], as well as whether cathepsin D occurs free or in bonds. Cathepsin D binding to the lysosomal membrane or a constant carrier increases the pH optimum [28]. The optimum also depends on


the structure of protein molecule. Denaturated proteins undergo cathepsin D hydrolysis at a higher pH as compared to native proteins. Moreover, denaturation frequently increases protein susceptibility to the action of cathepsin D.

Complexification of hemoglobin with haptoglobin reduces the optimum pH from 3.5 to 2.8 for degradation and simultaneously causes a 50% decrease in degradation rate 50% (Fig. 5) [29].

**Material preparation, conditions and specificity of assays**


For diagnostics purposes, the activity and concentration of cathepsin D are determined in blood plasma, secretions, body fluids, excretions, tissue homogenates and in isolated lysosomes [31-34].

Plasma is obtained by centrifugation of blood collected to 3.8% sodium citrate (9:1 v/v ratio). Blood serum is not useful for cathepsin D activity determination. Plasma activity of cathepsin D is found to be lower than its serum activity [35]. Higher serum activity of cathepsin D indicates its release from platelets



**Fig. 5.** pH profiles of proteolyses by cathepsins. The ordinate represents the hydrolytic activity in arbitrary units. ○, free Hb; ●, Hb-Hp complex; △, pepstatin inhibitor for both [30].

that occurs after blood collection [35]. The amount of the released enzyme depends on platelet count and susceptibility of these cells to the release. Therefore, for diagnostic purposes, cathepsin should be determined in blood plasma. Cells from secretions, body fluids and excretions are removed by centrifugation directly after collection, prior to measurement of cathepsin D activity. Preparation of cell and tissue material for this measurement consists in homogenization and fractionation of homogenate by centrifugation/ultracentrifugation. In cells and tissues, cathepsin D activity is assessed in the whole homogenate (total activity), cytosole (free activity) and in lysosomes (bound activity). The activity of cathepsin D lysosomal fraction can only be roughly estimated due to heterogeneity of lysosomes and their partial sedimentation with other organelles [36]. The whole homogenate is prepared in 0.15 mol/l KCl using a flow homogenizer, in which tissue passes only once and at a definite time through the working area of the cutting blade or knife homogenizer [37,38]. Other methods used to prepare the whole homogenate include pulverization under liquid nitrogen, using a hand or mechanical [39,40] pulverizer. The homogenate, irrespective of the mode of preparation employed, is filtered through nylon cloth (pore size 0.12-0.15 nm) [37,41]. The activity of cathepsin D is determined in a noncentrifuged filtrate. Centrifugation causes sedimentation of approximately 20-30% of cathepsin D activity with fragments of lysosomal and



**Fig. 6.** Activity (●) and stability (■) of cathepsin D as a function of temperature [57].

cell organelle membranes [42,43]. In order to obtain cytosole and lysosomes, homogenate is prepared in 0.25 mol/l saccharose, using a Potter-Elvehjem homogenizer with smooth walls of a glass cylinder and a teflon piston, between which there is a 0.22 mm gap [44]. Cytosole is separated from lysosomes through homogenate ultracentrifugation [45,46] or precipitation of lysosomes at pH 5.0 [47]. The soluble cathepsin D fraction found in the solution constitutes supra-sediment after ultracentrifugation at 100000 x g, for one hour. Noncovalent interactions (ionic, hydrophobic, Me<sup>2+</sup> cation bridges) condition cathepsin binding to the membranes. Due to substantial durability of lysosomes, after a 48h storage in an isotonic environment at a temp. of 0-2°C, only 5-10% of cathepsin D passes to the environment. The material submitted for determination is stored in 10% DMSO or 25% glycerol at a temp. of -20°C or in a frozen state, in a freezer (temp. -75°C) or in a liquid nitrogen (temp. -182°C) [48,49].

Procathepsin D, at an acidic pH, undergoes rapid autoactivation. Its active form does not require activators and does not possess endogenous cell inhibitors. As plasma  $\alpha$ 2-macroglobulin does not suppress the action of cathepsin D at an acidic pH, total activity of this proteinase in plasma is determined *in vitro*. The *in vivo* activation and action of cathepsin D is conditioned by the acidic environment of lysosomes (pH 4.5-5.5). Interlysosomal pH is measured using one of the methods described [50-52]. The propeptide cleaved in this process is reported to have a certain regulatory role in procathepsin D activation [53,54].

The most common substrate used to determine cathepsin D activity is a 6% HCL-denaturated globin with urea [55] or the one obtained after treatment of hemoglobin with HCL-acidified acetone [56]. Hemoglobin digestion by cathepsin D takes place at 37°C. Elevation of the reaction temperature to 40-45°C causes only a slight increase in the reaction products. At higher temperatures, the enzyme becomes inactivated (Fig. 6). The incubation time determines the increase




Fig. 7. pH dependence of cathepsin D conformation and activity in solution. Enzyme activity (solid line) and enzyme stability (dash line) of cathepsin D as a function of pH [61].

in degradation products within the absorbance range of 0.2 to 0.6. In low-activity material, the sample volume should be relatively large whereas the volume of hemoglobin with a final concentration of 1-2% – relatively small [11]. A cathepsin D sample of 200-500 ng is sufficient for a single determination [49]. When the activity is very low, the sample should be densified using immunoprecipitation technique [58] or by one of the standard methods [59]. The pH optimum of cathepsin D activity depends on the type of substrate and the composition and ionic strength of a buffer. The buffers with the ionic strength ranging between 0.01 to 0.1 mol/l are used: glycine buffer (pH 2.2 – 3.0), formate buffer (pH 2.6 – 4.8), acetate buffer (pH 3.6 – 5.6), and universal Britton-Robinson buffer (pH 1.81 – 11.94) [60]. The Britton-Robinson buffer with various pH values is supplemented with appropriate amounts of NaCl to ensure the same ionic strength [60]. The correlation between cathepsin and pH, as well as stability of this proteinase at various pH values are shown in Fig. 7.

### Determination of activity and concentration

The quantitative assessment of cathepsin D is based on its catalytic properties (activity measurement) and antigenic properties (concentration measurement). In the activity measurement, the number of active molecules is determined, whereas in the concentration measurement the total number of all molecules, both active and inactive, is estimated. Since procathepsin D does not need activators and does not have endogenous cell inhibitors, its total activity can be determined in tissue material. The actions of other endopeptidases and exopeptidases found in the non-fractionated material are eradicated by their inhibitors (Table 1). Pepstatin, the inhibitor of cathepsin D and other aspartyl proteinases, does not inhibit the activities of cysteine

Table 1. Inhibitors of different proteinase classes.

Inhibitor, concentration	Proteinase class
Pepstatyna, 1 $\mu\text{mol/l}$ DAN + $\text{Cu}^{2+}$ , 1 mmol/l	Aspartyl
PCMB, 1 mmol/l E-64, 10 $\mu\text{mol/l}$	Cysteinyl
PMSF, 1 mmol/l 3,4-DCI, 0,1 mmol/l	Serylowe
1,10-fenantrolina, 1 mmol/l EDTA, 2 mmol/l	Metalloprotease
Inhibitors cocktail E-64, 0,4 mmol/l 3,4-DCI, 2 mmol/l 1,10-fenantrolina, 2 mmol/l	Cysteinyl Seryl Metalloprotease

E-64 – L-3-carboxy-2,3-trans-epoxy-propionyl-leucylamido/guanidylne/buthane; 3,4-DCI – 3,4-Dichloroisocoumarin (3,4-Dichloro-2-benzopyran-1-one).

Table 2. Vulnerability of human aspartyl proteases to inhibitors; + inhibitory effect, - lack of inhibition [62].

Inhibitor	Cathepsin D	Cathepsin E	Pepsin	Renin
Pepstatin A	+	+	+	+
<i>Ascaris sp.</i> derived inhibitor	-	+	+	-
Antibodies against cathepsin D	+	-	-	-

cathepsins, seryl cathepsins or metalloproteases, and inhibitors of these cathepsins do not suppress cathepsin D action. A properly-selected set of inhibitors allows differentiation of cathepsin D from cathepsin E, pepsin and rennin, which are also aspartyl proteinases (Table 2).

Cathepsin D cleaves only certain peptide bonds in proteins and does it in a defined sequence. In this process, mass concentration remains stable whereas molar concentration of its fragments increases. The activity of cathepsin D is most frequently manifested by the amount of generated degradation products. More seldom, its activity is shown as the number of microequivalents of cleaved peptide bonds per time unit.

### Native, denaturated and labeled proteins

Protein susceptibility to the action of cathepsin D is determined by the composition and sequence of amino acid residues in the polypeptide chain and by its spatial structure. Hence, different susceptibility of various proteins to the action of this proteinase (Table 3).

The  $\alpha$ - and  $\beta$ -globins which build the hemoglobin molecule are most prone to the action of cathepsin D.


**Table 3.** Degradation of different proteins by cathepsin D in different pH [57].

Protein	pH		
	3,0	3,5	5,0
Hemoglobin	100	90	30
$\alpha$ -globulin	12	12	8
$\beta$ -globulin	10	10	5
$\gamma$ -gloglobulinbulina	0	0	0
Albumin	15	12	5
Fibrynogen	0	0	0
Fibrine	12	8	8
Casein	15	20	12

The hemoglobin molecule contains two  $\alpha$ - chains and two  $\beta$ -globin chains forming dimers composed of one chain  $\alpha$  and one chain  $\beta$ . The  $\alpha$  chain included in bovine hemoglobin molecule is built up of 141 whereas  $\beta$  chain contains 146 amino acid residues. Their amino acid sequence and the cleavage site are presented in Fig. 8. At the junctions of the homonymous subunits ( $\alpha$ - $\alpha$ ,  $\beta$ - $\beta$ ), polar amino acid residues are found to predominate, whereas the heteronymous subunits show the predominance of ( $\alpha$ - $\beta$ ) hydrophobic residues. Hemoglobin tetramer is stabilized mainly due to hydrophobic interactions between the heteronymous subunits. Each  $\alpha$ - and  $\beta$ -globin chain contains one hem and one ferrous ion ( $Fe^{2+}$ ). Hem accounts for 4% and iron for 0.34% of the hemoglobin molecule. The polypeptide  $\alpha$ - and  $\beta$ -globin chains are in 80% constituted by the  $\alpha$ -helix structure and in 20% by a disordered structure [63,64]. The fact that bovine

A Hemoglobin $\alpha$ -chain			
Cleaved	Bovine	Human	Canine
1	V*LSPA	V*LSPA	V*LSPA
24	AAEY*GAEA	AGEY*GAEA	ADGY*GGEA
32	LERM*FLSF	LERM*FLSF	LDRM*FOSF
109	LLVT*LASH	LLVT*LAAH	LLVT*LACH
134	ANVS*TVLT	ASVS*TVLT	AAVS*TVLT
137	STVL*TSKY	STVL*TSKY	STVL*TSKY
Hemoglobin $\beta$ -chain			
Cleaved	Bovine	Human	Canine
6	TAAE*KA <sup>AV</sup>	TPEE*KSAS	TAAE*KS <sup>LV</sup>
14	VTAF*WG <sup>KD</sup>	VTAL*WE <sup>KV</sup>	VSGL*WG <sup>KV</sup>
30	LGRL*LV <sup>VY</sup>	LGRL*LL <sup>VY</sup>	LGRL*LI <sup>VY</sup>
31	GRL*LV <sup>VY</sup>	GRL*LV <sup>VY</sup>	GRL*LI <sup>VY</sup>
40	TQRF*FES <sup>F</sup>	TQRF*FES <sup>F</sup>	TQRF*FDS <sup>F</sup>
44	FES <sup>F</sup> *GDLS	FES <sup>F</sup> *GDLS	FDS <sup>F</sup> *GDLS
53	ADAV* <sup>M</sup> N <sup>NF</sup>	PDAV* <sup>M</sup> G <sup>NP</sup>	PDAV* <sup>M</sup> S <sup>NA</sup>
B Hemoglobin $\alpha$ -chain			
Cleaved	Bovine	Human	Canine
29	AEAL*ERM <sup>F</sup>	AEAL*ERM <sup>F</sup>	GEAL*DR <sup>TF</sup>
33	ERM <sup>F</sup> *LS <sup>FP</sup>	ERM <sup>F</sup> *LS <sup>FP</sup>	DR <sup>TF</sup> *OS <sup>FP</sup>
36	FLSF*PT <sup>TK</sup>	FLSF*PT <sup>TK</sup>	FOS <sup>F</sup> *PT <sup>TK</sup>
45	YFPH*FD <sup>LS</sup>	YFPH*FD <sup>LS</sup>	YFPH*FD <sup>LS</sup>
109	LLVT*LASH	LLVT*LAAH	LLVT*LACH
110	LVTL*ASH <sup>L</sup>	LVTL*AAH <sup>L</sup>	LVTL*ACH <sup>H</sup>
129	LDKF*LAN <sup>V</sup>	LDKF*LAS <sup>V</sup>	LDKF*LA <sup>AV</sup>
Hemoglobin $\beta$ -chain			
Cleaved	Bovine	Human	Canine
6	TAAE*KA <sup>AV</sup>	TPEE*KAS <sup>V</sup>	TAAE*KS <sup>LV</sup>
14	VTAF*WG <sup>KD</sup>	VTAL*WE <sup>KV</sup>	VSGL*WG <sup>KV</sup>
30	LGRL*LV <sup>VY</sup>	LGRL*LL <sup>VY</sup>	LGRL*LI <sup>VY</sup>
31	GRL*LV <sup>VY</sup>	GRL*LV <sup>VY</sup>	GRL*LI <sup>VY</sup>
40	TQRF*FES <sup>F</sup>	TQRF*FES <sup>F</sup>	TQRF*FDS <sup>F</sup>
44	FES <sup>F</sup> *GDLS	FES <sup>F</sup> *GDLS	FDS <sup>F</sup> *GDLS
129	LQAD*FQ <sup>KV</sup>	VQAA*YQ <sup>KV</sup>	VQAA*YQ <sup>KV</sup>

**Fig. 8.** (A) Human cathepsin D – known cleavage sites in bovine hemoglobin are shown alongside orthologous sites in human and canine hemoglobin. (B) Schistosoma japonicum cathepsin D – known cleavage sites in human hemoglobin are shown alongside equivalent sites in bovine and canine hemoglobin [65].



**Fig. 9.** Denaturation of hemoglobin by HCl and its influence on globin degradation by cathepsin D. (A) – naive hemoglobin; (B) –  $\alpha$  and  $\beta$  denaturated globin.

$\alpha$ - and  $\beta$ -globin chains do not possess disulphide bridges that would reduce the action of the proteinase is their advantage.

Mixtures of  $\alpha$ -globin and  $\beta$ -globin obtained by hemoglobin denaturation with hydrochloric acid, hydrochloric acid and urea, sodium hydrogen, sodium hydrogen and urea are most frequently used to determine cathepsin D activity [66]. Due to their action, Hem is detached, bonds that join  $\alpha$ - and  $\beta$ -globin chains torn apart, their structure undergoes denaturation and becomes more susceptible to cathepsin D action (Fig. 9). The mixture of  $\alpha$ - and  $\beta$ -globin, obtained in that way is traditionally referred to as 'hemoglobin'. High solubility in a wide pH range (1.0-12.0) is another advantage of  $\alpha$ - and  $\beta$ -globins, allowing them to be used for the determination of pH optima for cathepsin D activity. The globin concentration used to determine the activity of cathepsin D ranges from 0.5 to 5%. Denaturation with the involvement of urea increases at the same time globin solubility in a wide pH range and the number of non-precipitated TCA products of its degradation [67,68].


Similarly, hemoglobin treatment with HCL-acidified acetone causes hem detachment, disruption of connections between globins and their denaturation [56,71-73]. Simultaneously, globin molecules undergo precipitation and are separated from hem dissolved in acetone by centrifugation.

Globin hydrolysis termination is accomplished using trichloroacetate acid (TCA) that precipitates undecomposed globin. The final concentration of TCA accounts for 0.1 – 0.8 mol/l (2.5 – 20.0%). Depending on TCA concentration, products with vari-


ous molecular masses are precipitated. Application of higher TCA concentrations facilitates separation of a thick precipitate by filtration or centrifugation, but reduces the number of products left in the solution. Degradation products soluble in TCA are separated from the precipitated protein by filtration or centrifugation. In a clear filtrate/supernatant, the concentration of hydrolysis products is determined by direct measurement of absorbance at 280 nm [5] or fluorescence [74,75], dependent on tyrosyl and tryptophanyl residues. However, direct measurement of absorbance at 280 nm in nonpurified material is loaded with error. Nucleic acids contained in such a material are degraded by nucleases and released nucleotides increase the measurement values [76,77]. Degradation products are more frequently determined following addition of staining reagent, via absorbance measurement at a suitable wavelength. The reagents used for staining of degradation products include copper reagent (microbiuretic) and Folin and Ciocalteu's reagent applied separately or simultaneously, ninhydrin reagent, 2,4,6-trinitrobenzenesulphic acid and o-ftalaldehyde [78-81].

Hemoglobin denaturation and assessment of cathepsin D activity described below is recommended for routine assays.

A. Hemoglobin denaturation: hemoglobin (6g) is suspended in 35 ml of distilled water, with addition of 15 ml 1 mol/l HCl and then incubation is carried out at 37°C for 30 minutes. The pH is elevated up to 3.5 by means of 1 mol/l NaOH, next distilled water is added to 90 ml and 10 ml of 2.0 mol/l acetate buffer (pH 3.5); a 6% solution of globin in acetate buffer, pH 3.5, is obtained in this way.



**Fig. 10.** Scheme of reaction of fluorescamine with proteins as the basis for the development of a method for the measurement of proteolytic degradation. The striped area represents fluorescence and its relative size stands for the relative fluorescence of the N-terminal and  $\gamma$ -amino groups after reaction with fluorescamine [89].



**Fig. 11.** Reaction of cathepsin D on methyl-<sup>14</sup>C-glycinated hemoglobin (o-o) and acid-denatured hemoglobin (Δ-Δ) as a function of (a) time, (b) protein concentration and (c) pH [91].

B. Assay: 0.1 ml of 6% globin (pH 3.5) is added to 0.4 ml sample (homogenate, plasma, the same pH) and incubation is performed at 37°C for 1-6 hours (depending on activation). The reaction is discontinued by addition of 0.5 ml of 5% TCA acid containing 2.5 mol/l urea. The sample in which TCA acid was added at time zero is referred to as 'control'. All samples undergo centrifugation (1500 x g, 2°C, 30 min). The amount of 0.25 ml of supernatant fluid is supplemented with 1.5 ml of copper reagent (1 volume of 0.5% CuSO<sub>4</sub> x H<sub>2</sub>O in 1% sodium citrate x 5 H<sub>2</sub>O and 30 volumes of 10% sodium carbonate). After 10 minutes, 0.25 ml of Folin and Ciocalteu's reagent diluted with distilled water (2:1 v/v ratio) is added and after further 30 minutes, absorbance is measured at 750 nm. Results are read

from a calibration curve designed according to standard tyrosine solutions (10-200 nmol/ml).

The use of labeled hemoglobin/globin considerably simplifies the methods applied to determine the activity of cathepsin D. As a result of fragmentation of a globin molecule, the molecule bound marker after addition of trichloroacetic acid remains in the solution, its concentration reflecting the molecule activity. The globin labeled with chromophores, fluorophores and radioelements are used [3,82]. The chromophore consists of the nitric group (nitro-globin) and azo group (azo-globin). Fluorophores include fluorescamine, fluorescein isothiocyanate, rhodamine B isothiocyanate, 1-amino-8-naphthalene sulfonic acid [83-88]. Fig. 10 presents the reaction of amino acids



**Table 4.** Comparison of assay methods for cathepsin D [65]. The values given are approximate, and are expressed in terms of the unit of assay I, which corresponds to about 1,2 µg human cathepsin D. The estimate of enzyme required per assay assumes that an unincubated blank is required for each chemical method, but is unnecessary in the radiochemical method.


Method	Sample required, miliunit		
	per probe	per assay	concentration/ml
I. $E_{280}$ nm	60	120	120
II. Folin and Ciocalteu + $Cu^{2+}$	30	60	30
III. Radiochemical	2	2	16

with fluorescamine. The radioelements used for hemoglobin labeling include  $^3H$ ,  $^{14}C$ ,  $^{125}I$  and  $^{131}I$  [90-92]. Addition of a pigment or a fluorizing compound causes substantial changes in globin structure and is frequently associated with reduced susceptibility to cathepsin D action. Addition of a radioelement does not reduce globin susceptibility to cathepsin D (Fig. 11). Moreover, the use of the radioelement-labeled globin requires considerably smaller amount of cathepsin and ensures linear increment of reaction products even at its high activity [5]. Whereas the application of  $A_{280}$  nm measurement requires 144 ng and Folina-Ciocalteu's reagents – 72 ng, the radiometric method needs only 4.8 ng of cathepsin D (Table 4).


$\beta$ -endorphin has been lately recommended as a substrate for cathepsin D activation measurement [93]. This polypeptide is built up of 31 amino acid residues (Fig. 12). Products of  $\beta$ -endorphin digestion are separated and assessed quantitatively by HPLC technique. Fig. 13 illustrates the differences between cathepsin D and cathepsin E actions on  $\beta$ -endorphin and substance P.

Myoglobin [94], casein [95-97] and albumin [98,99], both labeled and non-labeled with chromophore, fluorophore and radioelement are less frequently used to determine cathepsin D.

The effect of protein digestion by cathepsin D is also assessed by measuring its loss, either without separation or after separation of degradation products. The spectrophometric method [100], the viscosimetric method [101-103], the nephelometric method [104,105] and the plate method [106] are used to assess protein loss without separation of the non-degraded protein from degradation products. In the spectrophometric method, reduction in the number of peptide bonds is evaluated by measuring the absorbance at 225 nm. The viscosimetric method assesses a decrease in viscosity due to protein molecule breakdown into smaller fragments and enables measurement of the activity of endopeptidases contained in a mixture together with exopeptidases which



**Fig. 12.** Amino acid sequence of bovine  $\beta$ -endorphin [93]. Arrow indicates attacks by cathepsin D (-Leu17-Phe18-).



**Fig. 13.** Dependence on pH of the hydrolysis of  $\beta$ -endorphin (A) and substance P (B) by cathepsins D (●) and E (○) [93].

have no effect on the stickiness of protein molecules. The nephelometric method estimates the intensity of light dispersed after addition of a protein precipitating reagent. The tannin method is the most useful nephelometric method [104]. In the plate methods, such cathepsin D substrates as globin, casein, gelatin or fibrin are placed in a nonsoluble carrier (agar, starch) in Petri plates [4]. A definite volume of the material is placed on plates with a micropipette or filter paper disc saturated with the solution studied. The plates are then incubated at 37°C and after 1-96 hours, depending on the activity of proteinases in the sample, the size of the digested protein field is read directly or after sprin-

**Table 5.** Methods for cathepsin D activity measurements using different polypeptides [7,23].



Substrate	Products measurement method
Denaturated hemoglobin	Sectrophotometric (Folin-Ciocalteu reagent + Cu <sup>2+</sup> )
Fluorogen tagged hemoglobin	Fluorimetric
Radioelement tagged hemoglobin	Radiometric
Alkaline protein	Sectrophotometric (Sakaguchi reagent)
Proteoglycans	Viscosimetric
$\beta$ -endorfine	High pressure liquid chromatography (HPLC)

klung the plate with a sublimate or sulfosalicylic acid. The plate method is used to detect traces of proteolytic activity, which requires a long incubation time. This method allows a continuous observation of the digestion process. Also other methods can be used to assess the increase in protein degradation products without separation of the non-degraded protein. During protein digestion, the number of amino and carboxyl groups that appear in the non-buffered environment is the measure of enzyme activity [107]. Addition of formol [98] or ethanol reverses dissociation of amino groups, whereas the number of carboxyl groups is determined by titration with titrated NaOH solution, in the presence of phenolftalein. Acetone causes a decrease in dissociation of carboxyl groups and free amino groups are titrated in this solvent solution using the titrated HCl solution, in the presence of phenol red. Another possibility is precipitation of non-degraded protein by means of copper hydroxide, which at the same time forms soluble complexes with protein digestion products [4]. After filtration, the concentration of color complexes is assessed colorimetrically. Protein loss is also measured after precipitation with TCA acid, washing out of acid, drying and assessing by the weight-based method or after dissolving the sediment in sodium carbonate solution by a chosen method of quantitative protein determination.

The most recommended methods for cathepsin D activity determination using proteins and polypeptides are listed in Table 5.







### Synthetic peptides

Identification of amino acid residues forming peptide bonds cleaved by cathepsin D in natural peptides helped generate synthetic peptides. Proteins as macromolecular substrates bind to numerous cathepsin D-binding sites (Fig. 14), whereas peptides bind to only one cathepsin D-binding site. Due to this, partly denat-

**Fig. 14.** Binding and hydrolysis of protein (p) and synthetic peptide (sp) by naive cathepsin D (n-CD) and denaturated cathepsin D, bound by  $\alpha$ 2-M or an antibody (d-CD). S<sub>1</sub>, S<sub>1</sub>' – substrate binding sites; CS – cathepsin D catalytic site.**Fig. 15.** Products of protein and synthetic peptide degradation by cathepsin D. • – hydrophobic amino acid rests, → – cleaved peptide bond.

urated cathepsin D bound to  $\alpha$ 2-macroglobulin or to cathepsin D antibodies hydrolyzes peptides but not proteins (Fig. 15).

Cathepsin D hydrolyzes internal peptide bonds in the peptides with at least five amino acid residues in the molecule [108]. These peptides are built up of L-amino acids and contain hydrophobic amino acid

Detector Group	Spectral Characteristics
para-nitroaniline (pNA) 	Yellow color when cleaved from peptide (405 nm). May also be coupled with p-dimethylamino-cinnamaldehyde to yield a colored schiffbase compound (570 nm).
(colorimetric)	
2-naphthylamine (BNA) 	Fluorometric when cleaved from peptide (excitation 340 nm/emission 425 nm) or Azo coupling reaction with fast blue B as red product (525 nm).
(fluorometric or colorimetric)	
4-methoxy-2-naphthylamine (4 MNA) 	Fluorometric when cleaved from peptide (excitation 340 nm/emission 425 nm) or Azo coupling fast blue B as red product (525 nm).
(fluorometric or colorimetric)	
5-aminoisophthalic acid (AIE) dimethyl ester 	Fluorometric when cleaved from peptide (excitation 335 nm/emission 430nm) or coupling via Bratton Marshall Reaction to yield colored product.
(fluorometric or colorimetric)	
7-amino-4-methylcoumarin (MCA) 	Fluorometric when cleaved from peptide (excitation at 380 nm/emission 460 nm).
(fluorometric)	
7-amino-4-trifluoromethylcoumarin (AFC) 	Yellow color when cleaved from peptide (380 nm) or fluorometric (excitation 400 nm/emission 505 nm).
(colorimetric or fluorometric)	

General Structure of Peptide B-(AA)<sub>n</sub>-D  
Where B (Blocking Group), (AA)<sub>n</sub> (Peptide), n (1 to 4 amino acids)  
D (Detector Group)

**Fig. 16.** Function groups used in spectrophotometry and fluorimetry [109].

residues at the site susceptible to cathepsin D action. With peptide chain elongation, the number of grafted peptide bonds increases. The N-terminal amino group and C-terminal carboxyl group of these peptides can be either free or blocked, and may contain proline residue or D-amino acid residue. In non-fractionated material, the terminal blockage protects these substrates against the action of amino peptidases and carboxyl peptidases.

Spectrophotometric or fluorimetric methods are used to determine the products of peptide hydrolysis. Functional groups conditioning the peptide usefulness in spectrophotometric and fluorimetric measurements are

presented in Fig. 16. Direct and indirect spectrophotometry can be distinguished.

In direct spectrophotometry, chromogenic peptide substrates, listed in Table 6, are used. The chromogenic substrates containing the amino acid residue corresponding to cathepsin D specificity, with an attached chromogenic group, allow direct measurement of the amount of the generated product. In the chromogenic substrates, the nitrophenylalanylic residue is most frequently at the position P1 or P1'. For instance, the course of Phe-Ala-Ala-Phe(NO<sub>2</sub>)-Phe-Val-Leu-OM4P hydrolysis leads to generation of Phe-Ala-Ala-Phe(NO<sub>2</sub>), which is determined by

**Table 6.** Chromogenic peptide substrates for cathepsin D used in direct spectrophotometry.

Peptide	Literature
H-Phe-Gly-His-Phe/NO <sub>2</sub> -Phe-Ala-OMe	Voynick (1971)
H-Phe-Ala-His-Phe/NO <sub>2</sub> -Phe-Val-Leu-OMe	Ferguson (1973)
H-Phe-Gly-His-Phe/NO <sub>2</sub> -Phe-Ala-Phe-OMe	Ferguson (1973)
H-Phe-Gly-His-Phe/NO <sub>2</sub> -Phe-Val-Leu-OMe	Ferguson (1975)
H-Phe-Gly-His-Phe/NO <sub>2</sub> -Phe-Ala-Phe-OMe	Fruton (1976)
H-Leu-Gly-Arg-Phe-Phe-Gly-Gly-OH	Marks (1980)
H-Phe-Ala-Ala-Phe/NO <sub>2</sub> -Phe-Val-Leu-OMe	Agarwal (1983)
H-Phe-Gly-Gly-Phe/NO <sub>2</sub> -Phe-Val-Leu-OMe	Agarwal (1983)
Pro-Thr-Glu-Phe-Phe/NO <sub>2</sub> -Arg-Leu-OH	Kay (1983)
Glp-His-Phe/NO <sub>2</sub> -Phe-Ala-Leu-NH <sub>2</sub>	Pohl (1983)
H-Gly-Gly-His-Phe/NO <sub>2</sub> -Phe-Ala-Leu-NH <sub>2</sub>	Pohl (1983)
H-Pro-Thr-Glu-Phe-Phe/NO <sub>2</sub> -Arg-Leu-OH	Dunn (1984)
H-Lys-Pro-Ala-Glu-Phe-Phe/NO <sub>2</sub> -Arg-Leu-OH	Dunn (1985)
H-Pro-Thr-Glu-Phe-Phe/NO <sub>2</sub> -Arg-Leu-OH	Dunn (1986)
Pro-Pro-Thr-Ile-Phe-Phe/NO <sub>2</sub> -Arg-Leu-OH	Jupp (1990)
H-Lys-Pro-Ile-Glu-Phe-Phe/NO <sub>2</sub> -Arg-Leu-OH	Scarborough (1993)
Pro-Thr-Glu-Phe-Phe/NO <sub>2</sub> -Arg-Leu-NH <sub>2</sub>	Bolger (1996)
Dansyl-Ala-Gly-Phe/NO <sub>2</sub> -Phe-Gly-OB	Katwa (1996)

absorbance measurement at 310 nm and the results are read from a calibration graph prepared using standard Phe(NO<sub>2</sub>) solutions.


The peptides used to determine cathepsin D activity with indirect spectrophotometry are listed in Table 7. The reaction products are stained with ninhydrin or by diazotization method. In peptides with blocked N-terminal amino group, the number of amino groups generated via peptide bond hydrolysis is estimated by the ninhydrin method. The course of the reaction is illustrated in Fig. 17. In peptides with the p-aminobenzoic acid residue attached to the C-terminal amino acid, e.g. H-D-Phe-Ser-Phe-Phe-Ala-Ala-p-aminobenzoate, cathepsin D cleaves the Phe-Phe bond. The originating Phe-Ala-Ala-p-aminobenzoate is affected by aminopeptidase M (Fig. 18). The diazotization reaction is performed with released p-aminobenzoate (Fig. 19).

The fluorogenic residue is found in fluorogenic substrates at the position P1 or P1' (Table 8). The released fluorophor exhibits optic properties that differ in the emission wavelength compared to the initial compound and can be used for quantitative assessment. As shown in Fig. 20, the fluorescence intensity of Lys-Pro-Leu-Leu-Tyr-Phe(NO<sub>2</sub>)-Leu-Leu is very low. The maximum intensity of fluorescence of Phe(NO<sub>2</sub>)-Leu-Leu is observed at 303 nm (excitation at 260 nm). In a 12-peptide AMCA-Glu-Glu-Lys-Pro-Ile-Ser-Phe-Phe-Arg-Leu-Gly-Lys(biotinyl)-NH<sub>2</sub>, cathepsin D cleaves the Phe-Phe bond. The N-fragment containing AMCA-fluorophor and the C-terminal fragment containing Lys-(biotinyl)-NH<sub>2</sub>-fluorophor are formed.


Incorporation of the D-amino acid residue in the peptide structure reduces its susceptibility to the action of cathepsin D. In the hexapeptide Gly-Phe-Leu-Gly-

**Table 7.** Peptide substrates for cathepsin D in indirect spectrophotometry.

Peptide	Reagent	Literature
N-Ac-Gly-Phe-Leu-Gly-Phe-OH	ninhydrin	Keilova (1971)
Z-Pro-Phe-His-Ile-Ile-Val-Tyr-Ser-βNA	diazonium	Reinharz (1971)
Bz-Arg-Gly-Phe-Phe-Leu-4-methoxy-βNA	diazonium	Woessner (1971)
Bz-Arg-Pro-Phe-Phe-Ile-4-methoxy-βNA	diazonium	Woessner (1971)
H-D-Phe-Ser-Phe-Phe-Ala-Ala-p-Abz	diazonium	Orlowski (1984)
H-Asp-Arg-Val-Tyr-Ile-Ile-Pro-Phe-Ile-Leu-Leu-Val-Tyr-Ser-OH	ninhydrin after HPLC	Poe (1984)
H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Ile-Val-Ile-His-OH	ninhydrin after HPLC	Cumin (1987)
H-Asp-Val-Arg-Tyr-Ile-Ile-Pro-Phe-Ile-Leu-Leu-Val-Tyr-Ser-OH	ninhydrin after HPLC	Stammers (1987)
H-D-Phe-Ser-Phe-Phe-Ala-Ala-Abz-OH	diazonium	Adenis (1995)
H-D-Phe-Ser-/O-CH <sub>2</sub> -C <sub>6</sub> H <sub>5</sub> -Phe-Phe-Ala-Ala-PAB	diazonium	Couissi (1987)




**Fig. 17.** The course of the ninhydrin reaction with aminoacids is as follows: 1. ninhydrin (2,2-dihydroxy-1,3-indandione) reacted with amino acid; 2. the intermediate formed as the first reaction product; 3. intermediate gives rise to dipolar ion by decarboxylation and dehydration; 4. the dipolar ion hydrolyzes, producing the amine; 5. the amine condenses with a second molecule of ninhydrin to give Ruhemann's Purple.




**Fig. 18.** Degradation catalyzed by cathepsin D and aminopeptidase M [87].

Phe-Leu, the Phe-Leu bond is cleaved by cathepsin D [108]. Hydrolysis of hexapeptides having an analogous structure but containing D-amino acids is substantially hindered; besides, they inhibit breakdown of the hexapeptide composed exclusively of L-amino acids. Susceptibility to hydrolysis and degree of inhibition of cathepsin D by these analogues depend on distribution and number of D-amino acids in the molecule (Table 9). The analogues having only one D-amino acid in the molecule, localized at the maximum distance from the site sensitive to the proteinase action, show major susceptibility and poorest inhibitory effect. However, the analogues containing D-amino acid found within the peptide bond that is being cleaved, as well as two amino acids and cyclic hexapeptide are neither hydrolyzed nor exhibit an inhibitory effect [147].

Glycosylation of peptides reduces their susceptibility to the action of cathepsin D. As shown in Table 10, glycosylation of the asparaginian acid residue at the position P4 reduces over fourfold and at the position P4' twofold the susceptibility of the nonapeptide Abz-



**Fig. 19.** Diazotization of β-naphthylamine. 1 – β-naphthylamine; 2 – sodium nitrite; 4 – ammonium sulphamate; 6 – ethylenediamine;



**Fig. 20.** Fluorescence emission spectra of Lys-Pro-Leu-Leu-Tyr-Phe(NO<sub>2</sub>)-Leu-Leu and Lys-Pro-Leu-Leu-Phe-(NO<sub>2</sub>)-Tyr-Leu-Leu [146].

F-H-L-V-I-H-N-E-EDDnp to the action of cathepsin D. Simultaneous glycosylation at the positions P4 and P4' – makes this peptide resistant to this proteinase.

The synthetic peptides used as cathepsin D substrates are dissolved in dimethylsulfoxide (DMSO), dimethylformamide (DMF) or methanol (Me) [8]. The 1-2% concentration of these solvents does not affect cathepsin D activity. The initial solutions of the substrates have a concentration ranging between 50 and 250 mmol/l. Prior to use, they are dissolved to obtain a concentration of 5 – 25 mmol/l, using a buffer.

**Table 8.** Fluorogenic peptide substrates for cathepsin D.

Peptide	Measurement method	Literature
Bz-Arg-Gly-Phe-Phe-Pro-4βNA	fluorimetric	Smith (1975)
Bz-Arg-Gly-Phe-Phe-Leu-4βNA	fluorimetric	Smith (1975)
Abz-Ile-Glu-Phe-Phe/NO <sub>2</sub> -arg-Leu-NH <sub>2</sub>	fluorimetric	Bogitsh (1986)
Ac-Glu-Glu/Fdans/-I.ys-pro-Ile-Cys-Phe-Phe-Arg-I.eu-Gly-I.ys/DABCYL/-Glu-NH <sub>2</sub>	fluorimetric	Baldwin (1993)
Abz-Ile-Glu-Phe-Phe/NO <sub>2</sub> -Arg-Leu-NH <sub>2</sub>	fluorimetric	Beyer (1996)
Abz-Ala-Ala-Phe-Phe-Ala-Ala-Ded	fluorimetric	Filipowa (1996)
Abz-Ala-Ala-Phe-Phe-Ala-Ala-pNA	fluorimetric	Filipowa (1996)
Ac-Glu-Asp/FDANS/-I.ys-Pro-Ile-I.eu-Phe-Phe-Arg-I.eu-Gly-I.ys/DABCYL/-Glu-NH <sub>2</sub>	fluorimetric. after HPLC	Gulnik (1997)
NO <sub>2</sub> -Tyr-Gly-Se-Thr-Phe-Phe-I.ys-Abz	fluorimetric	Peterson (1998)
NO <sub>2</sub> -Tyr-Gly-Thr-Gln-Phe-Phe-Lys-Abz	fluorimetric	Petersen (1998)
Abz-Ile-Glu-Phe/NO <sub>2</sub> -Phe-arg-Leu-NH <sub>2</sub>	fluorimetric	Verity (1999)
MOCac-Gly-I.ys-Pro-Ile-I.eu-Phe-Phe-Arg-I.eu-I.ys/Dnp/-D-arg-NH <sub>2</sub>	fluorimetric	Yasuda (1999)
MOCac-Gly-His-Pro-Ile-Ile-Phe-Phe-Arg-I.eu-I.ys/Dnp/-D-arg-NH <sub>2</sub>	fluorimetric	Yasuda (1999)
H-Lys-Pro-Leu-Leu-Tyr-Phe(NO <sub>2</sub> )-Leu-Leu	fluorimetric	Yonezawa (1999)
H-Lys-Pro-Leu-Leu-Phe(NO <sub>2</sub> )-Tyr-Leu-Leu	fluorimetric	Yonezawa (1999)
Abz-Ala-Ile-Ala-Phe-Phe-Ser-Arg-Glu-EDDnp	fluorimetric	Pimenta (2001)
Abz-Ala-Ile-Glu-Phe-Phe-Ser-Arg-Gln-FDDnp	fluorimetric	Pimenta (2001)
Abz-Ala-Ile-Lys-Phe-Phe-ser-Ala-Gln-Thr-Asn-Arg-Gln-EDDnp	fluorimetric	Pimenta (2001)
MOCac-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys/Dnp/-Asp-Arg-NH <sub>2</sub>	fluorimetric	Komai (2004)
MOCac-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-arg-Lys-/Dnp/-Arg-Arg-NH <sub>2</sub>	fluorimetric	Komai (2004)
AMCA-Glu-Glu-I.ys-Pro-Ile-Ser-Phe-Phe-Arg-I.eu-Gly-I.ys/biotinyl/-NH <sub>2</sub>	fluorimetric. after HPLC	Baechle 2005)

**Table 9.** Cleavage of hexapeptide Gly-Phe-Leu-Gly-Phe-Leu and its diastereomers and inhibition of release of the dipeptide Gly-Phe from the substrate Gly-Phe-Leu-Gly-Phe-Leu in the presence of its D-isomers by cathepsin D [108].

Hexapeptide*	Cleavage, %	Inhibition, %
Gly---Phe-Leu-Gly---Phe---Leu	100.0	0.0
Gly---Phe-Leu-Gly---Phe-D-Leu	6.0	89.2
Gly---Phe-Leu-Gly-D-Phe---Leu	3.0	73.4
Gly-D-Phe-Leu-Gly---Phe---Leu	0.0	63.1
Gly-D-Phe-Leu-Gly-D-Phe---Leu	0.0	0.0
Gly---Phe-Leu-Gly---Phe---Leu	0.0	0.0

\* - arrow indicates cleaved peptide bond

**Table 10.** Kinetic constants for hydrolysis of internally quenched fluorescent peptides by human cathepsin D [148]. Arrows indicate the cleavage site, NDH – no detected hydrolysis.

Substrates-P1-P1'	Cathepsin D, kcal/Km
(GlcNAcβ) Abz-N-I-I-L- V-I-I-N-E-EDDnp	113
(GlcNAcβ) Abz -F-H-I- V-I-H-N-F-EDDnp	263
(GlcNAcβ) (GlcNAcβ) Abz-N-I-I-L- V-I-I-N-E-EDDnp	NDH
Abz-F-H-I-V-I-H-N-F-EDDnp	454




Fig. 21. Hydrolysis of hemoglobin by cathepsin D as function of enzyme concentration.




Fig. 22. Inhibition curve obtained by addition of increasing amounts of pepstatin to the cathepsin D; substrate – hemoglobin; titration curve: a – ideal, b – real [149].

### Determination of concentration

The concentration and content of active cathepsin D molecules in blood plasma and tissue homogenates are determined based on the results of its activity measurement and the calibration graph presenting the correlation between the activity and concentration (Fig. 21). Titration of a catalytic site using pepstatin [149] or dansyl-pepstatin [150], and placing the results on the graph to help read the concentration value is another way used to determine active cathepsin D molecule concentration (Fig. 22).

Total concentration and content of both inactive and active cathepsin D are determined using specific antibodies by the immunoenzymatic method ELISA [151,152] and by radioimmunoenzymatic methods [153,154] (Table 11).

Cathepsin D possesses a few sequential and conformational antigen determinants, against which antibodies are produced. Antibodies contained in anti-

Table 11. Immunoenzymatic methods for estimation of cathepsin D concentration.

Method	Reagent (company)
Immunoenzymatic method (ELISA)	Enzyme-linked immunosorbent assay Kit (Ciba Corning Diagnostic, Italy; Triton Diagnostics, USA).
Rapid immunoenzymatic method (ELISA)	Cathepsin D Rapid Format ELISA assay Kit (Calbiochem, Suisse)
Immunoradiometric method (IRMA)	Immunoradiometric assay IRMA Cath-D Kit (Cis Bio-International, Gif-Sur-Yvette, France)





Fig. 23. Effect of antiserum ratio on cathepsin D activity in pH=3.2 [159,160]. ○ – before centrifuging; ● – in supernatant; ▲ – in precipitate.


serum, isolated antibodies and monovalent Fab (fragment antigen binding) fragments of immunoglobulins bind to cathepsin D [155-158]. Formation of bonds between cathepsin D and antibodies is most intense at pH above 3.0-5.0. Antigen determinants and a catalytic site of cathepsin D are located at distant sites of the molecule. This, however, does not hinder access of the substrate to the catalytic site. Only removal of the cathepsin D-antibody complex from the solution by centrifugation leads to the loss of activity in the supernatant (Fig. 23). Fig. 24 illustrates the principle of the immunoenzymatic method, whereas Fig. 25 shows the principle of the radioimmunoenzymatic method of cathepsin D assay.

### Determination of tissue and cell location of cathepsin D

Tissues and organs differ in cathepsin D content [2,93]. Table 12 shows the content and activity of this enzyme in the rat organs. Cell composition differs between organs as well as between healthy and pathological tissues. The liver is characterized by high



**Fig. 24.** Schema for performing the immunoassay of cathepsin D [161].



**Fig. 25.** Schema for performing the immuno-radiometric assay of cathepsin D [161].

diversity of cell composition. The respective types of cells in this organ show varied cathepsin D activity (Table 13). Among the cells that build up the liver, Kupfer cells exhibit the highest cathepsin D activity. Cathepsin D is localized in hepatic lysosomes (Table 14) that account for 1% of total hepatocyte volume, their number ranging from 300 to 400.

In cytochemical and histochemical techniques, it is postulated that the morphological structures should be maintained unchanged so that they could be recognized microscopically. To do this, the cell and tissue materials need to be properly prepared. Therefore, the classical fixation methods are replaced by the cryostat sectioning technique. This procedure is the method of choice, especially in histoenzymology, for the performance of enzymatic reaction. The final product of the reaction is perceptible under optical or electron microscopes.

Cathepsin D can be localized in cells and tissues using cyto/histochemical and immunocyto/histochemical techniques [163-170]. The former employ methyl-mercury pepstatin derivative, biotin-labeled pepstatin and biman-labeled pepstatin [171-174], as well as chemical compounds shown in Fig. 26. In the latter techniques, tissue sections are fixed using a set of reagents AMeX (acetone, methyl benzoate, xylene)

[175,176]. Polyclonal antibodies (DAKO A/S Glostrup, Denmark) bind to cathepsin D epitopes. Cathepsin D is visualized by means of avidin-biotin peroxidase complex (ABC) kit [177,178]. 3-amino-9-ethylcarbazole (AEC) is used as chromogene, yielding a red color reaction product.

### Determination of activity and concentration of cathepsin D inhibitors

Cathepsin D has neither endogenous lysosomal nor cytosolic inhibitors. When lysosomes become damaged and cathepsin D passes to the intracellular fluid and blood plasma, it is neutral pH and  $\alpha 2$ -macroglobulin ( $\alpha 2$ -M) that prevent uncontrolled proteolysis [179,180].

$\alpha 2$ -M is synthesized in fibroblasts and then passes to the intracellular fluid, lymph and blood. In plasma,  $\alpha 2$ -M occurs in a concentration of 260.0 mg/100 ml (3.3  $\mu$ mol/l). Approximately 20% of plasma cathepsin D is bound to  $\alpha 2$ -M [181,182]. The remaining 80% occurs in a free state as procathepsin D, the inactive precursor not bound to  $\alpha 2$ -macroglobulin. The cathepsin D binding to pepstatin hinders interaction with  $\alpha 2$ -macroglobulin, due to which the amount of cathepsin D bound to this inhibitor decreases to approximately



**Table 12.** Levels of cathepsin D in rat and mokey tissues.

Rat		Tissue		Monkey	
Hydrolytic activity $\beta$ F, nmol/min/mg tissue protein	CTSD ng/mg tissue protein			Hydrolytic activity $\beta$ F, nmol/min/mg tissue protein	CTSD ng/mg tissue protein
14.0	220	cerebrum	frontal cortex	8.1	140
-	-	-	hypothalamus	6.3	110
-	-	-	pituary	11.0	190
8.2	130	cerebellum		9.3	160
14.0	190	thymus		6.4	110
17.0	270	lung		5.6	98
4.4	69	heart		2.5	44
9.3	150	liver		3.9	68
12.0	99	stomach		-	-
3.5	49	duodenum		15.0	250
4.2	61	jejunum		40.0	700
4.2	59	ileum		20.0	350
4.3	65	colon		23.0	400
23.0	330	spleen		36.0	630
12.0	190	kidney		4.0	70
69.0	1090	adrenal		45.0	790
5.6	88	pancreas		8.1	140
12.0	150	urinary bladder		30.0	530
2.5	39	muscle		0.62	11
12.0	180	lymph node		43.0	750
7.8	98	bone marrow		5.6	97
0.05	<1	serum		0.01	<1
<0.01	<1	blood cells	erythrocyte	5.3	93
-	-	-	leucocyte	<0.01	<1

**Table 13.** Activity of cathepsin D in perenchymal, sinusoidal, endothelial and Kupffer cells isolated from the rat liver [162].

Cells suspension	Cathepsin D activity, nmoles tryptophan	
	nmoles/min/mg protein	nmoles/min/ $10^6$ cells
Perenchymal cells	0.52	0.66
Sinusoidal lining cells	8.44	0.51
Endothelial cells	6.12	0.25
Kupffer cells	17.97	2.11

**Table 14.** Intracellular distribution of cathepsin D in rat liver [36]. Ex – cytoplasmic extract, N – nuclear fraction, M – mitochondrial fraction, L – lysosomal fraction, Mic – microsomal fraction, S – soluble fraction (final supernatant).

Fractions	Absolute values		Percentage values	
	Nitrogen mg/g	Cathepsin D units/g	Nitrogen	Cathepsin D
Ex + N	32.3	1.46	100	100
N	4.3	0.06	13.3	4.0
M	6.2	0.51	16.3	35.0
L	2.4	0.63	7.4	42.9
Mic	7.9	0.11	24.4	7.5
S	12.2	0.25	37.5	17.1




Fig. 26. Diagram representing the three chemistries for the cytochemical staining of proteases that liberate 4-methoxy- $\beta$ -naphthylamine.

8%. The concentration of  $\alpha_2$ -M is determined with antibodies by the nephelometric method, laser nephelometry and radial immunodiffusion. The activity of  $\alpha_2$ -macroglobulin is assessed by the enzymatic method by measuring the reduction in proteolytic activity in a standard testing system [183]. Cell and tissue  $\alpha_2$ -M is also localized. Binding to  $\alpha_2$ -macroglobulin inhibits the action of cathepsin D on macromolecular substrates and only slightly on micromolecular substrates. The inhibitory activity of  $\alpha_2$ -macroglobulin towards cathepsin D occurs at pH 5.5-6.0, but not at a lower pH because of structural instability [185].  $\alpha_2$ -macroglobulin is inactivated with methylamine [186,187]. This proteinase inhibitor prevents uncontrolled proteolysis [180] via binding, inhibition and removal of proteinases from plasma and intracellular fluid. The  $\alpha_2$ -M-proteinase complexes are captured by specific macrophage receptors [188], undergo endocytosis and are transported into lysosomes. Then, the complexes undergo digestion and the receptors return to the cell surface.

The  $\alpha_2$ -M differs from typical proteinase inhibitors in binding mode and low specificity. The catalytic site of cathepsin D bound to  $\alpha_2$ -M is free. The micromolecular substrates and inhibitors, but not the macromolecular ones, have access to this site. Cathepsin D and  $\alpha_2$ -M show a two-stage interaction: in the first stage, cathepsin D cleaves the specific peptide bonds situated within the polypeptide chain of the inhibitor, thus causing conformational changes within the inhibitor; in the second stage – the enzyme is surrounded and access of macromolecular substrates is blocked. Exopeptidases cannot cleave the peptide bonds situated within the  $\alpha_2$ -M polypeptide chain and thus their activity is not blocked by this inhibitor.

Exogenous cathepsin D inhibitors include such synthetic compounds as 1,2-epoxy-3-(p-nitrophenoxy)-propan, diazoacetyl-dl-norleucin methyl ester, pepstatin and its derivative [116,189] and peptide inhibitors found in spare organs of many plant species [116,190,191]. The activity of exogenous cathepsin D inhibitors is determined in a test in which: 1/ cathepsin releases the reaction product in the amount corresponding to the absorbance of 0.50; 2/ the inhibitor blocks 50% of enzyme activity. The inhibitor activity is calculated from the formula: inhibitor, U/ml/min =  $(d \times r) : t$ , in which: d means difference in the quantity of the reaction products in a test without and with inhibitor, r – inhibitor dilution, t – incubation time. The inhibitor sample is diluted when activity suppression exceeds 50%. The septopeptide Pro-Thr-Glu-Phe-Phe(NO<sub>2</sub>)-Arg-Leu [116] or globin [191] is used to determine the inhibitor activity.

The enzyme- inhibitor molar ratio is determined from the plot presenting the correlation between cathepsin D activity and inhibitor concentration [192,193]. The inhibitor concentration causing a 50% reduction in the enzyme activity, referred to as the inhibitory dose 50 (ID<sub>50</sub>), is taken into consideration in the assessment and expressed in  $\mu$ mol/l [189]. The numerical value of ID<sub>50</sub> is used to compare the strength of the inhibitory effect of various inhibitors. The therapeutic application of the inhibitor is preceded by determination of its toxicity expressed as the lethal dose 50 (LD<sub>50</sub>), as established for experimental animals [194].

Determination of the effect of preincubation time with inhibitor on the measurement shows its immediate or progressive action. The measurement of inhibitor activity can also be affected by the sequence in which reagents are added: inhibitor – enzyme – sub-

strate or inhibitor – substrate – enzyme [196,197]. Determination of the activity of cathepsin D inhibitors in non-fractionated extracts from cells of microorganisms and plant tissues can be burdened with error, as these samples may also contain, apart from these inhibitors, proteinases that function in an acidic pH [180]. Prior to homogenization, the inhibitor and proteinase are found in different cell compartments and come into contact only after homogenization. These proteinases can be both sensitive and insensitive to the inhibitors and in both cases reduce the measurement, either suppressing the inhibitor activity or leading to its proteolytic inactivation, respectively. These proteinases can also degrade and inactivate cathepsin D. In the case of stable micromolecular inhibitors (plant extract, homogenate, plasma, urine), proteases are inactivated thermally or with trichloroacetate acid or perchloric acid. The precipitated proteins are eliminated via centrifugation. Trichloroacetate acid is removed from the supernatant by ether extraction, whereas perchloric acid is precipitated using potassium hydroxide. The inhibitor concentration is determined based on the antiproteolytic activity. The calibration graph is drawn to show the correlation between cathepsin D activity and inhibitor concentration. Determination of cathepsin D activity after addition of a deproteinized sample allows reading the concentration of the inhibitor.

In studies on cathepsin D inhibitors, especially in plant samples, the presence of nonspecific cathepsin D inactivators, including polyphenol compounds, should be excluded [198].

### Diagnostic significance of cathepsin D

In physiological conditions, only small amounts of cathepsin D pass to the intercellular environment, to blood and body fluids via exocytosis of procathepsin and cathepsin D, excretion of residue bodies and disintegration of physiologically exhausted cells [199-201]. The pathological conditions, occurring with hypoxia, acidemia and especially necrosis, are characterized by damage to lysosomal and cellular membranes, and release of increased amounts of cathepsin D [202]. Enhanced synthesis of cathepsin D and insufficiency of the intercellular apparatus transporting procathepsin may contribute to the increased escape of cathepsin D out of cell [203-205]. The activity of cathepsin D in plasma depends also on its uptake by monocytes/macrophages in the liver and spleen [202-206]. An impaired uptake or saturation of these cells with phagocytized material may cause a rise in plasma cathepsin D activity. The half-life of cathepsin D in blood amounts to 60-90 minutes [207-208].

For diagnostic purposes, the activity and level of cathepsin D are assessed in homogenate (total activity), in the cytoplasmic fraction, in the lysosomal frac-

tion, in blood plasma, in secretions (saliva, gastric juice), excretions (urine, feces), and body fluids (peritoneal fluid, pleural fluid, cerebrospinal fluid).

The activity/level of cathepsin D and its inhibitors in plasma and body fluids are calculated per cell count in solid tissues per 1g of wet or dry tissue or 1 µg of DNA [209-211]. Determination of cathepsin D activity in homogenate per ml of protein for diagnostic purposes or in toxicological investigations is not justified and may lead to interpretation errors. With the same activity of cathepsin D in homogenate – the activity is high when the protein content is low, and the activity is low when the protein content is high. Measurement of cathepsin D activity per ml of protein is useful only for preparatory tasks and when purification degree of this proteinase is calculated.

Also other endopetidases involved in protein digestion at an acidic pH can be found in plasma and tissue homogenates, namely cathepsin B and cathepsin L (pH 5.5), cathepsin E (pH 2.5) and pepsin (pH 2.0) [212-214]. The pH ranges in which these enzymes function are found to overlap. The specificity of cathepsin D determination increases following addition of the cathepsin B and L inhibitor, *i.e.* L-trans-epoxysuccinyl-Leu-4-guanidinobutylamide (E-64), and the cathepsin E and pepsin inhibitor isolated from *Ascaris lumbricoides* (All) to the incubation mixture. The activity of cathepsin D is lower in plasma than in serum [247]. Hemolysis does not affect the measurement. When an immunological method is used, other cathepsins have no effect on the determination of cathepsin D concentration/content. The lower limit of cathepsin D measurability is 0.012 nmol/l. Plasma cathepsin D level should range from 9.9 nmol/l (healthy women) to 10.6 nmol/l (healthy men) [218,219].

The activity and concentration/level of cathepsin D are frequently found to overlap. However, sometimes the opposite situation may occur. The activity may be higher than the concentration when conformation masking or sequential epitopes condition the reactions with antibody, or lower when the molecule undergoes inactivation (denaturation) without impairment of its epitope.

The histochemically and immunohistochemically determined distribution of cathepsin D and its inhibitors (mainly  $\alpha$ 2-M) in cells and tissues are presented on color microphotographs. The reaction intensity is assessed semiquantitatively using the following scale: lack of reaction (-), weakly positive reaction ( $\pm$ ), positive reaction (+), strongly positive reaction (++)

### Conclusion

Determination of the activity/concentration and cell/tissue distribution of cathepsin D and its inhibitors plays a major role in biochemistry, pathobiochemistry and diagnostics. Development of analytical methods

involves a search for specific and sensitive substrates (beta-endorphin, synthetic fluorogenic peptides) and new analytical techniques: HPLC [145,220], capillary electrophoresis [221-223], fluorimetry in the near infrared region [224], flow cytofluorimetry [225-229], western blot [230-232], immunohistochemical techniques [168,169], fluorescence microscopy [233,234] and electron microscopy [235,236].

## References

- [ 1 ] Ochmaru E, Sakai H, Saku T, Kunimatsu K, Kato Y, Kato I, Yamamoto K. Characterization of hemoglobin-hydrolyzing and proteinases in human and rat neutrophils. *J Biochem.* 1990;108:1009-1015.
- [ 2 ] Yamoto K. Cathepsin E and cathepsin D, w: *Proteases. New perspectives*, red. V Turk. Birkhauser Verlag, Basel. 1999:59-71.
- [ 3 ] Blott EJ, Griffiths GM. Secretory lysosomes. *Nature Rev.* 2002;3:122-131.
- [ 4 ] Worowski K, Mariak T. Metody pomiaru aktywności enzymów proteolitycznych. *Diagn Lab.* 1973;9:219-232.
- [ 5 ] Barrett AJ. Cathepsin D and other carboxyl proteinases, in: *Proteinases in mammalian cell and tissue* ed. AJ Barrett. *Nort-Holland Publ Comp, Amsterdam.* 1977:209-248.
- [ 6 ] Lanoe J, Dumnigan J. Improvements of the Anson assay for measuring proteolytic activities in acidic pH range. *Anal Biochem.* 1978;89:461-471.
- [ 7 ] Worowski K, Ostrowska H. Cathepsin D. *Post Biol Kom.* 1980;7:119-147.
- [ 8 ] Sarth G, de la Motte RS, Wagner FW. Protease assay methods, in *Proteolytic enzymes a practical approach*, ed. RJ Beynon, JS Bond. IRL Press, Oxford. 1994:25-55.
- [ 9 ] Reis RCM, Sorgine MHF, Coelho-Sampaio T. A novel methodology for the investigation of intracellular proteolytic processing in intact cells. *Eur J Cell Biol.* 1998;75:192-197.
- [ 10 ] Roszkowska-Jakimiec W, Worowska A, Gacko M, Worowski K. Determination of activity and concentration of cathepsin D and their inhibitors. *Diagn Lab.* 2000;36:103-119.
- [ 11 ] Greczaniuk A, Roszkowska-Jakimiec W, Gacko M, Worowska A. Oznaczanie aktywności katepsyny D w osoczu krwi przy użyciu hemoglobiny zdenaturowanej kwasem solnym. *Diagn Lab.* 2001;36:97-101.
- [ 12 ] Roszkowska-Jakimiec W, Gacko M, Worowska A. Method of cathepsin D activity and concentration determination. *Diagn Lab.* 2007;43:275-282.
- [ 13 ] Richo GR, Conner GE. Structural requirements of procathepsin D activation and maturation. *J Biol Chem.* 1994;269:14806-14812.
- [ 14 ] Mullins C, Bonifacino JS. The molecular machinery for lysosome biogenesis. *BioEssays.* 2001;23:333-343.
- [ 15 ] Minarowska A, Gacko M, Karwowska A, Minarowski Ł. Human cathepsin D. *Folia Histochem Cytobiol.* 2008;46:23-38.
- [ 16 ] Erickon AH. Biosynthesis of lysosomal endopeptidases. *J Cell Biochem.* 1989;40:31-41.
- [ 17 ] Krishnan V, Narasimhan TR, Safe S. Development of gel staining techniques for detecting the secretion of procathepsin D (52-kDa protein) in MCF-7 human breast cancer cells. *Anal Biochem.* 1992;204:137-142.
- [ 18 ] Dahmus NH, Label P, Kornfeld S. Mamoze 6-phosphate receptors and lysosomal enzyme targeting. *J Biol Chem.* 1989;264:12115-12118.
- [ 19 ] Larsen LB, Boisen A, Petersen TE. Procathepsin D cannot autoactivate to cathepsin D at acid pH. *FEBS Lett.* 1993;319:54-58.
- [ 20 ] Wittlin S, Rosel J, Hofmann F, Stover DR. Mechanism and kinetics of procathepsin D activation. *Eur J Biochem.* 1999;265:384-393.
- [ 21 ] Wright LM, Levy ES, Patel NP, Alhadeff JA. Purification and characterization of cathepsin D for human breast tissue. *J Prot Chem.* 1997;16:171-181.
- [ 22 ] Bazel S, Ferry KV, Shoarinejd F, Laury-Kleintop LD, Lange MK, Tachovsky T, Longo S, Tucker S, Alhadeff JA. Analysis of breast tissue cathepsin D isoforms from patients with breast cancer, benign disease and from normal controls. *Int J Oncol.* 1994;5:847-853.
- [ 23 ] van Noort JM, van der Drift ACM. The selectivity of cathepsin D suggests an involvement of the T-cell epitopes. *J Biol Chem.* 1989;264:14159-14164.
- [ 24 ] Cunningham M, Tang J. Purification and properties of cathepsin D from porcine spleen. *J Biol Chem.* 1972;251: 4528-4536.
- [ 25 ] Naduwimana J, Guenet L, Dorval I, Blayau M, Le Gall JY, Le Treut A. Proteases. *Ann Biol Clin.* 1995:251-264.
- [ 26 ] Cuervo AM, Paulmer A, Rivett AJ, Knecht E. Degradation of proteasomes by lysosomes in rat liver. *Eur J Biochem.* 1995;227:792-800.
- [ 27 ] Bohley P, Seglen PO. Proteases and proteolysis in the lysosome. *Experientia.* 1992;48:151-157.
- [ 28 ] Dimont S, Leech MS, Stahl PD. Cathepsin D is membrane-associated in macrophage endosomes. *J Biol Chem.* 1988;263:6901-6907.
- [ 29 ] Lim SK, Ferraro B, Moore K, Halliwell B. Role of haptoglobin in the hemoglobin metabolism. *Redox Report.* 2001;6:219-227.
- [ 30 ] Kimura H, Tsudzuki T, Murachi T. Proteolytic degradation of hemoglobin-haptoglobin complex by lysosomal enzymes from rat liver. *J Biochem.* 1975;77:909-912.
- [ 31 ] Kramar R, Lambrecht R, Raab W. *Die katheptische aktivitat im harn.* *Wien Klin Wschr.* 1970;82:410-411.
- [ 32 ] Dean RT, Barrett AJ. Essays in biochemistry ed. *PN Campbell WN Aldrige. Acad Press NY.* 1976;12:1-40.
- [ 33 ] Esumi H, Sato S, Sugimura T, Okasaki N. Purification and properties of an acid protease from human ascitic fluid. *Biochim Biophys Acta.* 1978;523:191-197.
- [ 34 ] Raab WP. Diagnostic value of urinary enzyme determination. *Clin Chem.* 1972;18:5-25.
- [ 35 ] Ostrowska H, Worowski K. Blood platelets – a source of cathepsin D activity in the serum. *Acta Haematol Pol.* 1982;13:13-16.
- [ 36 ] De Duve C, Pressman BC, Gianetto R, Wattiaux R, Appelmanns F. Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. *Biochem J.* 1955;60:604-617.
- [ 37 ] Karwowska A, Gacko M, Worowska A, Krupkowska A; Tissue fragmentation for biochemical studies. *Bromat Chem Toksycol.* 2006;39:199-202.
- [ 38 ] Panusz H. The influence of autolysis and homogenization techniques on the stability of preparations of subcellular fractions. *Ann Acad Med Lodzensis.* 1973;14,suppl.10:157-161.
- [ 39 ] Ladinsky H, Consolo S, Sanvito A. Simple apparatus for pulverization and rapid quantitative transfer of frozen tissue. *Anal Biochem.* 1972;49:294-297.
- [ 40 ] Obenauf RH. SPEX CertiPrep handbook of sample preparation and handling. *SPEX GertiPrep Inc Metuchen NJ USA.* 2002:26-54.
- [ 41 ] Wiśniewska-Knypl JM, Knobloch K, Jabłońska J, Ruta U. Decrease of tissue respiration, activity of oxoglutarate dehydrogenase and level of sulfhydryl groups in acute acrylonitrile intoxication in rats. *Med Pracy.* 1970;21:544-549.
- [ 42 ] Chyczewski L, Płoński A, Chyczewska E, Furman M, Ostrowska H, Nikliński J, Kozłowski M. Activity and tissue localization of cathepsin D in non small cell lung cancer. *Ann Acad Med Bialostoc.* 1997;42suppl1:217-229.

- [43] McIntyre GF, Erickson AH. Procathepsin L and D are membrane-bound in acidic microsomal vesicles. *J Biol Chem.* 1991;266:15438-15445.
- [44] Beaufay H. Methods for the isolation of lysosomes, in lysosomes a laboratory handbook, ed JT Dingle. *North-Holland Publ Comp Amsterdam.* 1972:1-32.
- [45] Leeighton F, Paole B, Beaufay H, Baudhuin P, Coffey JW, Fowler S, de Duve C. The large-scale separation of peroxisomes, mitochondria, and lysosomes from the livers of rats injected with triton WR-1339. *J Cell Biol.* 1968;37:482.
- [46] Storrie B, Madden EA. Isolation of subcellular organelles. *Meth Enzymol.* 1990;182:203-225.
- [47] Gacko M, Głowiński J, Skrzydlewska E, Worowska A, Głowiński S. Activity of enzymes of various subcellular localization in cytosol obtained after cell organelle precipitation at pH 5.0. *Ann Acad Med Bialostocensis.* 1996;41:341-346.
- [48] Sznajd J, Naskalski J. Determination of the activity of enzyme inactivated during catalytic process. *Diagn Lab.* 1978;14:127-133.
- [49] Turk V, Lah T, Kregar I. Cathepsin D, cathepsin E. In ed HU Bergmeyer *Methods of enzymatic analysis.* Verlag Chemie Weinheim. 1984:211-222.
- [50] Reijngoud DJ, Tager JM. Measurement of intralysosomal pH. *Biochem Biophys Acta.* 1973;297:174-179.
- [51] Okhuma S, Poole B. Fluorescence probe measurement of the intralysosomal pH in living cell and the perturbation of pH by various agents. *Proc Natl acad Sci USA.* 1978;75:3327-3331.
- [52] Van Dyke RW. Acidification of rat liver lysosomes: quantitation and comparison with endosomes. *Am J Physiol.* 1993;165:C901-C917.
- [53] Koelsch G, Mares M, Metcalf P, Fusek M. Multiple function of pro-parts aspartic proteinase zymogenes. *FEBS Lett.* 1994;343:6-10.
- [54] Masa M, Maresova L, Vondrasek J, Horn M, Jezek J, Mares M. Cathepsin D propeptide: mechanism and regulation of its interaction with the catalytic core. *Biochemistry.* 2006;45:15474-15482.
- [55] Shamberger RJ. Lysosomal enzyme changes in growing and regressing mammary tumors. *Biochem J.* 1969;111:375-383.
- [56] Marcinišzyn J, Hartsuch JA, Tang J. Mode of inhibition of acid proteases by pepstatin. *J Biol Chem.* 1976;251:7088-7094.
- [57] Ducastaing A, Azanza JL, Raymond J, Robin JM, Greach P. La cathepsin D de rate de cheval. II. Etude de quelques propriétés enzymatique. *Biochimie.* 1972;58:783-791.
- [58] Zuhlsdorf M, Imort M, Hasilik A, Von Fidura K. Molecular forms of beta-hexosaminidase and cathepsin D in serum and urine of health subjects and patients with elevated activity of lysosomal enzymes. *Biochem J.* 1983;213:733-740.
- [59] Zwierz K, Zych J. Concentration of the biological fluids. *Diagn Lab.* 1971;7:127-130.
- [60] Ciba J. *Poradnik chemika analityka.* Wyd N-T Warszawa. 1989;1:107.
- [61] Lee AY, Gulnik SV, Erickson JW. Conformational switching in an aspartic proteinase. *Nat Struct Biol.* 1998;5:866-871.
- [62] Kageyama T. Molecular cloning, expression and characterization of an Ascaris inhibitor for pepsin and cathepsin E. *Eur J Biochem.* 1998;253:804-809.
- [63] Brinkworth RI, Prociw P, Loukas A, Brindley PJ. Hemoglobin-degradation, aspartic proteases of blood-feeding parasites: substrate specificity revealed by homology models. *J Biol Chem.* 2001; 276:38844-38851.
- [64] Wharton SA, Hipkiss AR. Degradation of peptidase and proteins of different size by homogenates of human MRC5 lung fibroblasts. *FEBS Lett.* 1985;184:249-253.
- [65] Fruitier I, Gareau I, Piat JM. Cathepsin D is a good candidate for the specific release of stable hemorphin from hemoglobin *in vivo*: VV-hemorphin – 7. *Biochem Biophys Res Commun.* 1998;246:719-724.
- [66] Manning JM, Dumoulin A, Li X, Manning LR. Normal and abnormal protein subunit interaction in hemoglobins. *J Biol Chem.* 1998;173:19359-19362.
- [67] Geraci G, Parkhurst LJ, Gibson QH. Preparation and properties of alpha- and beta-chains human hemoglobin. *J Biol Chem.* 1969;244:46664-4667.
- [68] Wojtowicz MB, Odense P. The effect of urea upon the activity measurement of cod muscle cathepsin with hemoglobin substrate. *Can J Biochem.* 1970;48:1050-1053.
- [69] Rossi Fanelli A, Antonini A, Caputo A. Hemoglobin and myoglobin. *Adv Protein Chem.* 1964;19:74-222.
- [70] Wiederanders B, Kirschke H, Scharper S. The azocasein-urea-pepstatin assay discriminates between lysosomal proteinases. *Biomed. Biochim. Acta.* 1986;45:1477-1483.
- [71] Rossi-Fanelli A, Antonioni E, Caputo A. Studies on the structure of hemoglobin. I. Physicochemical properties of human globin. *Biochem Biophys Acta.* 1958;30:608-615.
- [72] Winterhalter KH, Huehns ER. Preparation, properties and specific recombination of alpha-beta-globin subunits. *J Biol Chem.* 1964;239:3699-3702.
- [73] Hu T, Li DX, Su ZG. Preparation and characterization of dimeric bovine hemoglobin tetramers. *J Prot Chem.* 2003;22:411-416.
- [74] Knook DL, Steyster EC. Isolated parenchymal, Kupffer and endothelial rat liver cells characterized by their lysosomal enzyme content. *Biochem Biophys Res Commun.* 1980;96:250-257.
- [75] Chrastil J. Spectrophotometric determination of tryptophan and tyrosine in peptides and proteins based on new color reactions. *Anal Biochem.* 1986;158:443-446.
- [76] Balasubramanin K, Deiss WP. Characteristics of thyroid lysosomal cathepsin. *Biochem Biophys Acta.* 1965;110:564-575.
- [77] Marrink J, Gruber M. Use of casein in assays for proteolytic activity in tissue extracts: a warning. *Biochim Biophys Acta.* 1966;118:438-439.
- [78] Lapresle C, Webb T. Study of a proteolytic enzyme from rabbit spleen. *Biochem J.* 1960;76:538-549.
- [79] McDonald CE, Chen LL. The Lowry modification of the Folin reagent for determination of proteinase activity. *Anal Biochem.* 1965;10:175-177.
- [80] Mednis A, Remold HG. A sensitive fluorometric assay for the determination of cathepsin D. *Anal Biochem.* 1972;49:114-138.
- [81] Rakoczy PE, Lai CM, Baines M, Di Grandi S, Fitton JH, Constable IJ. Modulation of cathepsin D activity in retinal pigment epithelial cells. *Biochem J.* 1997;324:935-940.
- [82] Opresko L, Wiley HS, Wallace RA. Proteins iodinated by chloramine-T method appear to be degraded at an abnormally rapid rate after endocytosis. *Proc Natl Acad Sci USA.* 1980;77:1556-1560.
- [83] Azaryan A, Akopyan T, Buniatian H. Cathepsin D from human brain: purification and multiple forms. *Biomed Biochim Acta.* 1983;42:1237-1246.
- [84] De Lumen BO, Tappel AL. Fluorescein-hemoglobin as a substrate for cathepsin D and other proteases. *Anal Biochem.* 1970;36:22-29.
- [85] Schwabe C. A fluorescent assay for proteolytic enzymes. *Anal Biochem.* 1973;53:484-490.
- [86] Bohley P, Stein S, Darman W, Udenfriend S. Fluorometric assay of proteins in the nanogram range. *Arch Biochem Biophys.* 1973;155:213-220.
- [87] Twining SS. Fluorescein isothiocyanate labeled casein assay for proteolytic enzyme. *Anal Biochem.* 1984;143:30-34.
- [88] Hortin GL, Warshawsky I, Laude-Sharp M. Macromolecular chromogenic substrates for measuring proteinase activity. *Clin Chem.* 2001;47:215-222.
- [89] Garesse R, Castell JV, Vallejo CG, Marco R. A fluorescamine-based sensitive method for the assay of proteinases, capable

- of detecting the initial cleavage step of a protein. *Eur J Biochem.* 1979;99:253-259.
- [90] Roth JS, Losty T, Wierbicki E. Assay of proteolytic enzyme activity using a 14C- labelled hemoglobin. *Anal Biochem.* 1971;42:214-221.
- [92] Williams HR, Lin TY. Methyl-14C-glycinated hemoglobin as a substrate for proteases. *Biochim Biophys Acta.* 1971;250:603-607.
- [92] Tack BF, Dean J, Eilat D. Tritium labelling of proteins to high specific radioactivity by reductive methylation. *J Biol Chem.* 1980;193:265-272.
- [93] Kageyama T, Moriyama A, Kato T, Sano M, Yonezawa S. Determination of cathepsin S and E in various tissues and cell of rat, monkey, and man by the assay with beta-endorphin and substrate P as substrate. *Zool Sci.* 1996;13:693-698.
- [94] Pennington RJ, Roninson JE. Cathepsin activity in normal and dystrophic human muscle. *Enzym Biol Clin.* 1968;9:175-182.
- [95] Adams CA, Robberts TC, Butler KC. Automated determination of proteolytic enzymes and of amino nitrogen by use of trinitrobenzenesulfonic acid (TNBS). *Anal Biochem.* 1976;70:181-186.
- [96] Gan ZB, Marquardt RR, Xiao H. Protease and protease inhibitor assays using biotinylated casein coated on a solid phase. *Anal Biochem.* 1999;268:151-156.
- [97] Visconti J, Pasternak K, Jodłowska-Jędrych B, Pedrycz A, Łopucki M, Szranke M, Hawryluk J, Czerny K, Dąbrowski W, Chichacz-Kwiatkowski B, Koziej J. Activity of cathepsin D and L in placentas from physiological and preterm deliveries as well as IUGR pregnancies. *Polich J Environ Stud.* 2008;17:175-180.
- [98] Langer J, Ansorge S, Bohley P, Kirschke H, Hanson H. Intracellular protein breakdown. I. Activity determination of endopeptidases using protein substrates. *Acta Biol Med Germ.* 1971;26:935-951.
- [99] Kucharz E. A modified micromethod for determination of cathepsin activity in blood serum. *Z Med Labor Diagn.* 1984;25:282-284.
- [100] Chavira R, Burnett TJ, Hageman JH. Assaying proteinases with azocoll. *Anal Biochem.* 1984;136:446-450.
- [101] Sapolsky AJ, Altman RD, Woessner JF, Howell DS. The action of cathepsin D in human articular cartilage on proteoglycans. *J Clin Invest.* 1973;52:624-633.
- [102] Sapolsky AJ, Howell DS, Woessner JF. Neutral proteases and cathepsin D in human articular cartilage. *J Clin Invest.* 1974;53:1044-1074.
- [103] Pałka J, Bańkowski E, Worowski K. Susceptibility of different types of collagen to the action of cathepsin D. *Ann Acad Med Biaslostoc.* 1984;29:53-58.
- [104] Meybaum-Katzenellenbogen W, Kołaczkowska M. The use of tannin in the examination of the digestion process of casein and fibrinogen by plasmin and for the preparation of the polypeptide and products of proteolysis. *Acta Physiol Pol.* 1970;21:235-242.
- [105] Koshy PT, Rowan AD, Life PF, Cawston TE. 96-well plate assays for measuring collagenase activity using 3H-acetylated collagen. *Anal Biochem.* 1999;275:202-207.
- [106] Fukal L, Kas J, Vodrazka Z. Survey of methods used for proteolytic enzymes activity determination. *Biochem Clin Bohemoslov.* 1985;14:109-120.
- [107] Ottesen M, Spector A. A comparison of two proteinases from *Bacillus subtilis*. *Comp Rend Trav Lab Carlsberg.* 1960;32:6-68.
- [108] Keilova H. On the specificity and inhibition of cathepsin D and B, in: *Tissue proteinases*, ed. AJ Barrett, JT Dingle. North-Holland Publ Comp, Amsterdam. 1971:45-67.
- [109] Smith RF. Contribution of histochemistry to the development of the proteolytic enzyme detection system in diagnostic medicine. *J. Histochem Cytochem.* 1983;31:199-209.
- [110] Voynick JM, Fruton JS. The comparative specificity of acid proteinases. *Proc Natl Acad Sci USA.* 1971;68:257-259.
- [111] Ferguson JB, Andrews JR, Voynick IM, Fruton JS. The specificity of cathepsin D. *J Biol Chem.* 1973;248:6701-6708.
- [112] Dingle JT, Dean RT. *Lysosomes in biology and pathology.* North-Holland Publ Co Amsterdam. 1975:193-249.
- [113] Fruton JS. The mechanism of the catalytic action of pepsin and related acid proteinases. *Adr Enzymol.* 1976;44:1-36.
- [114] Marks N, Benuck M, Hashim G. Specificity of brain cathepsin D: cleavage of model peptides containing the susceptible Phe-Phe regions of myelin basic protein. *J Neurosci Res.* 1980;5:217-223.
- [115] Agarwal N, Rich DH. An improved cathepsin-D substrate and assay procedure. *Anal Biochem.* 1983;130:158-165.
- [116] Kay J, Valler MJ, Dunn BM. Naturally-occurring inhibitors of aspartic proteinases. In: *Proteinase inhibitors: medical and biological aspects*, ed. Katunuma N. Japan Sci Soc Press Tokyo. 1983:201-210.
- [117] Pohl J, Baudys M, Kostka V. Chromophoric peptide substrates for activity determination of animal aspartic proteinases in the presence of their zymogens: a novel assay. *Anal Biochem.* 1983;133:104-109.
- [118] Dunn BM, Kammermann B, Mc Curry K. The synthesis, purification, and evaluation of a new chromophoric substrate for pepsin and other aspartyl proteases. *Anal Biochem.* 1984;138:68-73.
- [119] Dunn BM, Kay J. Design, synthesis and analysis of new synthetic substrates for the aspartic proteinases. *Biochem Soc Transact.* 1985;13:1041-1043.
- [120] Dunn BM, Jimenez M, Parten BF, Valler MJ, Rolph J, Kay J. A systematic series of synthetic chromophoric substrates for aspartic proteinases. *Biochem J.* 1986;237:899-906.
- [121] Jupp RA, Dunn BM, Jacobs JW, Vlasuk G, Arcuri KE, Weber DF, Perlow DS, Payne LS, Boger J, de Laszlo S, Chakravarty PK, ten Broeke J, Hangauer DG, Ondeyka D, Greenlee WJ, Kay J. The selectivity of statine-based inhibitors against various human aspartic proteinases. *Biochem J.* 1990;265:871-878.
- [122] Scarborough PE, Guruprasad K, Topham C, Richo GR, Conner GE, Blundell TL, Dunn BM. Exploration of subsite binding specificity of human cathepsin D through kinetics and rule-based molecular modeling. *Prot Sci.* 1993;2:269-276.
- [123] Bolger GT, Jaramillo J. Muscle aspartyl protease (cathepsin D) activity: detection using a chromophoric substrate and relation to wasting in DBA/2 mice implanted with leukemic L1210 tumor cells. *Canad J Physiol Pharmacol.* 1996;74:1141-1148.
- [124] Katwa LC, Tyagi SC, Campbell SE, Lee SJ, Cicila GT, Weber KT. Valvular interstitial cells express angiotensinogen and cathepsin D, and generate angiotensin peptides. *Int J Biochem Cell Biol.* 1996;28:807-821.
- [125] Reinhartz A, Roth M. Studies on pituitary cathepsin D with artificial substrates. *Enzyme.* 1971;12:458-466.
- [126] Woessner JF. *Acid proteases: structure, function and biology*, ed. J. Tang. Plenum Press New York. 1977:313-327.
- [127] Orłowski M, Orłowski R, Chang JC, Wilk E, Lesser M. A sensitive procedure for determination of cathepsin D activity in alveolar and peritoneal macrophages. *Mol Cell Biochem.* 1984;64:155-164.
- [128] Poe M, Wu JK, Lin TY, Bull NY, Slater EE. Renin cleavage of a human kidney renin substrate analogous to human angiotensinogen, H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Ser-OH, that is human renin specific and is resistant to cathepsin D. *Anal Biochem.* 1984;140:459-467.

- [129] Cumin F, Le-Nguyen D, Castro B, Menard J, Corvol P. Comparative enzymatic studies of human renin acting on pure natural or synthetic substrates. *Biochim Biophys Acta*. 1987;913:10-19.
- [130] Stammers DK, Dann JG, Harris CJ, Smith DR. Comparison of angiotensinogen and tetradecapeptide as substrates for human renin. Substrate dependence of the mode of inhibition of renin by a statine- containing hexapeptide. *Arch Biochem Biophys*. 1987;258:413-420.
- [131] Adenis A, Huet G, Zerimech F, Hecquet B, Balduyck M, Peyrat JP. Cathepsin B, L and D activities in colorectal carcinomas: relationship with clinico-pathological parameters. *Canc Lett*. 1995;96:267-275.
- [132] Couissi D, Dubois V, Remacle C, Schonne E, Trouet A. Western immunoblotting and enzymatic activity analysis of cathepsin D in human breast cancer cell lines of different invasive potential. Regulation by 17 $\beta$ -estradiol, tamoxifen and ICI 182,780. *Clin Exp Metastasis*. 1997;15:349-360.
- [133] Smith RE, Van Frank RM. The use of amino acid derivatives of 4-methoxy-b- naphthylamine for the assay and subcellular localization of tissue proteinases, w: *Lysosomes in biology and pathology*, ed. Dingle JT, Dean RT. North-Holland Publishing Co Amsterdam. 1975;4:193-249.
- [134] Bogitsh BJ, Kirshner KF. *Schistosoma japonicum*: ultrastructural localization of a hemoglobinase using mercury labelled pepstatin. *Exp Parasitol*. 1986;62:211-215.
- [135] Baldwin ET, Bhat TN, Gulnik S, Hosur MV, Sowder RC, Cachau RE, Collins J, Silva AM, Erickson JW. Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design. *Proc Natl Acad Sci*. 1993;90:6796-6800.
- [136] Beyer BM, Dunn BM. Self-activation of recombinant human lysosomal procathepsin D at a newly engineered cleavage junction, "short" pseudocathepsin D. *J Biol Chem*. 1996;271:15590-15596.
- [137] Filippova IY, Lysogorskaya EN, Anisimova VV, Suvorov LI, Oksenoit ES, Stepanov VM. Fluorogenic peptide substrates for assay of aspartyl proteinases. *Anal Biochem*. 1996;234:113-118.
- [138] Gulnik SV, Suvorov LI, Majer P, Collins J, Kane BP, Johnson DG, Erickson JW. Design of sensitive fluorogenic substrates for human cathepsin D. *FEBS Lett*. 1997;413:379-384.
- [139] Peterson JJ, Meares CF. Cathepsin substrates as cleavable peptide linkers in bioconjugates, selected from a fluorescence quench combinatorial library. *Bioconjug Chem*. 1998;9:618-626.
- [140] Verity CK, McManus DP, Brindley PJ. Developmental expression of cathepsin D aspartic protease in *Schistosoma japonicum*. *Int J Parasitol*. 1999;29:1819-1824.
- [141] Yasuda Y, Kageyama T, Akamine A, Shibata M, Kominami E, Uchiyama Y, Yamamoto K. Characterization of new fluorogenic substrates for the rapid and sensitive assay of cathepsin E and cathepsin D. *J Biochem*. 1999;125:1137-1143.
- [142] Yonezawa H, Uchikoba T, Arima K, Kaneda M. Fluorogenic substrates for cathepsin D. *Biosci Biotech Biochem*. 1999;63:1471-1475.
- [143] Pimenta DC, Oliveira A, Juliano MA, Juliano L. Substrate specificity of human cathepsin D using internally quenched fluorescent peptides derived from reactive site loop of kallistatin. *Biochem biophys Acta*. 2001;1544:113-122.
- [144] Komai T, Kawabata C, Amano M, Lee BR, Ichishima E. Todarepsin, a new cathepsin D from hepatopancreas of Japanese common squid (*Todarodes pacificus*). *Biochem Physiol Part B*. 2004;137:373-382.
- [145] Baechele D, Cansier A, Fischer R, Brandenburg J, Burster T, Driessen C, Kalbacher H. Biotinylated fluorescent peptide substrates for the sensitive and specific determination of cathepsin D activity. *J Pept Sci*. 2005;11:166-175.
- [146] Yokata S, Atsumi S. Immunoelectron microscopic localization of cathepsin D in lysosomes of rat nerve. *Histochemistry*. 1983;79:345-352.
- [147] Lin TY, Williams HR. Inhibition of cathepsin D by synthetic oligopeptides. *J Biol Chem*. 1979;254:11875-11883.
- [148] Juliano MA, Filira F, Gobbo M, Rocchi R, Del Nery E, Juliano L. Chromogenic and fluorogenic glycosylated and acetylglycosylated peptides as substrates for serine, thiol and aspartyl protease. *J Peptide Res*. 1999;53:109-119.
- [149] Knight CG. Active-site titration of peptidases. *Meth Enzymol*. 1995;248:85-101.
- [150] Yonezawa H, Uchikoba T, Kaneda M. Determination of pepstatin-sensitive carboxyl proteases by using pepstatinyldansyldiaminopropane (dansyl-pepstatin) as an active site titrant. *J Biochem*. 1997;122:294-299.
- [151] Pole AR. Immunological studies of tissue proteinases. *Subcell Biochem*. 1981;8:311-356.
- [152] Tumminello FM, Leto G, Pizzolanti G, Candiloro V, Crescimanno M, Crosta L, Flandina C, Montalto G, Soresi M, Carroccio A, Bascone F, Ruggeri I, Ippolito S, Gebbia N. Cathepsin D, B and L circulating levels as prognostic markers of malignant progression. *Anticanc Res*. 1996;16:2315-2320.
- [153] Brouillet JP, Spyrtos F, Hacene K, Fauque J, Freiss G, Dupont F, Maudelonde T, Rochefort H. Immunoradiometric assay of pro-cathepsin D in breast cancer cytosol: relative prognostic value versus total cathepsin D. *Eur J Cancer*. 1993;29A:1248-1251.
- [154] Gion M, Mione R, Dittadi R, Romanelli M, Pappagallo L, Capitanio G, Friede U, Barbazza R, Visona A, Dante S. Relationship between cathepsin D and other pathological and biological parameters in 1752 patients with primary breast cancer. *Eur J Cancer*. 1995;31A:671-677.
- [155] Weston PD, Poole AR. Antibodies to enzymes and their use, with specific reference to cathepsin D and other lysosomal enzymes. In: *Lysosomes in biology and pathology*, ed. Dingle JT. North Holland Elsevier Amsterdam. 1973;3:425-464.
- [156] Wildenthal K, Poole AR, Dingle JT. Influence of starvation on the activities and localization of cathepsin D and other lysosomal enzymes in hearts of rabbits and mice. *J Mol Cell Cardiol*. 1975;7:841-855.
- [157] Kopitar-Jerala N, Turk V. A procathepsin D specific monoclonal antibody that recognizes procathepsin D but not cathepsin D. *Immunol Lett*. 1999;70:211-212.
- [158] Kopitar-Jerala N, Puizdar V, Berbic S, Zavasnik-Bergant T, Turk V. A cathepsin D specific monoclonal antibody. *Immunol Lett*. 2001;77:125-126.
- [159] Dingle JT, Barrett AJ, Weston PD. Cathepsin D. Characteristics of immunoinhibition and the confirmation of a role in cartilage breakdown. *Biochem J*. 1971;123:1-13.
- [160] Koj A. The effect of antibodies on activity of enzymes. *Zesz Nauk UJ*. 1976;435:55-66.
- [161] Shaheen RM, Miseljić S, Doering DL, Wittliff JL. Comparison of cathepsin D determinations in human carcinomas by enzyme immunoassay and immunoradiometric assay. *J Clin Lab Anal*. 1995;9:351-358.
- [162] Knook DL. The role of lysosomal enzymes in protein degradation in different types of rat liver cells. *Acta Biol Med Germ*. 1977;36:1747-1752.
- [163] Stauber WT, Gauthier F, Ong SH. Identification and possible regulation of muscle cell lysosomal protease activity by exogenous protease inhibitors. *Acta Biol Med Germ*. 1981;40:1317-1322.
- [164] Musi M, Tessitore L, Bonelli G, Kazakova OV, Baccino FM. Changes in rat liver immunoreactive cathepsin D after cycloheximide. *Biochem Int*. 1985;10:283-290.

- [165] Rogier H, Freiss MG, Cavalie-Barthez G, Garcia M, Pau B, Rochefort H, Paolucci F. Two-site immunoenzymometric assay for the 52-kDa cathepsin D in cytosols of breast cancer tissues. *Clin Chem*. 1989;35:81-85.
- [166] Sakai H, Saku T, Kato Y, Yamamoto K. Quantitation and immunohistochemical localization of cathepsins E and D in rat tissues and blood cells. *Biochim Biophys Acta*. 1989;991:367-375.
- [167] Gohring UJ, Scharl A, Thelen U, Ahr A, Crombach G, Titus BR. Prognostic value of cathepsin D in breast cancer: comparison of immunohistochemical and immunoradiometric detection methods. *J Clin Pathol*. 1996;49:57-64.
- [168] Kasper M, Lackie P, Haase M, Schuh D, Müller M. Immunolocalization of cathepsin D in pneumocytes of normal human lung and in pulmonary fibrosis. *Virchows Arch*. 1996;428:207-215.
- [169] Długosz A, Chosia M. Immunocytochemical evaluation of gastric mucosal cathepsin D in peptic ulcer. *Pol J Pathol*. 1998;49:77-82.
- [170] Mylonas J, Makovitzky J, Richer DU, Jeschke U, Briese V, Friese K. Cathepsin D expression in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis. *Acta Histochem*. 2003;105:245-252.
- [171] Matthews ITW, Decker RS, Knight CG. Bimane-labelled pepstatin, a fluorescent probe for the subcellular location of cathepsin D. *Biochem J*. 1981;199:611-617.
- [172] Decker RS, Crie JS, Poolet AR, Dingle JT, Wildenthal K. Resistance to ischemic damage in hearts of starved rabbits. Correlation with lysosomal alternations and delayed release of cathepsin D. *Lab. Invest*. 1980;43:197-2007.
- [173] Yamato S, Hirabayashi Y, Uematsu H, Sugihara H. Histo- and cytochemical studies of cathepsin D using a specific inhibitor- pepstatin. *J Histochem Cytochem*. 1982;30:597-599.
- [174] Yamato S, Hirabayashi Y, Sugihara H. An improved procedure for the histochemical demonstration of cathepsin D by the mercury-labeled pepstatin method. *Stain Technol*. 1984;59:113-120.
- [175] Sato Y, Mukai K, Watanabe S, Gotoh M, Shimosato Y. The AMeX method a simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining. *Am J Pathol*. 1986;125:431-435.
- [176] Roger P, Montcourrier P, Maudelonde T, Brouillet JP, Pages A, Laffargue F, Rochefort H. Cathepsin D immunostaining in paraffin-embedded breast cancer cells and macrophages: correlation with cytosolic assay. *Human Pathol*. 1994;25:863-871.
- [177] Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. *J Histochem Cytochem*. 1981;29:577-580.
- [178] Arao J, Fukui H, Ono Y, Ueda Y, Chiba T, Fujimori T. Immunohistochemical localization of cathepsin D in colorectal tumors. *Dis Colon Rectum*. 2000;43:396-401.
- [179] Gonias SL, Pizzo SV. Conformation and protease binding activity of binary and ternary human alpha 2-macroglobulin-protease complexes. *J Biol Chem*. 1983;258:14682-14692.
- [180] Lah T, Vihar M, Turk V. Interaction of cathepsin D and pepsin with a2-macroglobulin. In: Aspartic proteinases and their inhibitors, ed. Kostka V. Walter de Gruyter Berlin. 1985:485-490.
- [181] Barrett AJ, Starkey PM. The interaction of a2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. *Biochem J*. 1973;133:709-724.
- [182] Thomas DJ, Richards AD, Kay J. Inhibition of aspartic proteinases by a2-macroglobulin. *Biochem J*. 1989;259:905-907.
- [183] Witt I, Tritschler W, Bablok W. Alpha-2-macroglobulin: reference values in serum and plasma with a chromogenic substrate (chromozym TRY). *J Clin Chem Biochem*. 1981;19:877-878.
- [184] Cassiman JJ, Van Leuven F, Van der Schueren B, Van den Berghe H. Immunohistochemical localization of human a2-macroglobulin in connective tissue. *Cell Tissue Res*. 1980;213:301-310.
- [185] Gaspar A, Skosey JL, Sequeira W, Teodorescu M. Detection of a2-macroglobulin-associated proteases in the plasma of patients with rheumatoid arthritis. *Clin Chem*. 1984;30:1517-1522.
- [186] Barrett AJ, Starkey PM, Munn EA. The unique nature of the interaction of a2-macroglobulin with proteinases. In: Proteinases inhibitors, ed. Fritz H, Tschesche H, Greene LG, Truscheit E. Springer-Verlag Berlin. 1974:72-77.
- [187] Swenson RP, Howard JB. Characterization of alkylamine-sensitive site in a2-macroglobulin. *Proc Natl Acad Sci USA*. 1979;76:4313-4316.
- [188] Blatrix C, Amouch P, Drouet J, Steinbuch M. Study on the plasmatic elimination of the a2-macroglobulin proteinase complexes. *Path Biol*. 1973;21:11-14.
- [189] Gacko M, Minarowska A, Karwowska A, Minarowski L. Cathepsin D inhibitors. *Folia Histochem Cytobiol*. 2007;45:291-313.
- [190] Karwowska A, Gacko M, Worowska A. Aktywność proteolityczna i hamowanie aktywności kathepsyny D przez z nasion soczewicy. *Bromat Chem Toksykol*. 2008;41:in press.
- [191] Karwowska A, Gacko M, Worowska M. Inhibition of pepsin activity and cathepsin D activity by seed extracts of plants consumed by human. *Bromat Chem Toksykol*. 2008;41:258-261.
- [192] Barrett AJ, Dingle JT. The inhibition of tissue acid proteinases by pepstatin. *Biochem J*. 1972;127:439-441.
- [193] Chang Y, Prusoff WH. Relationship between the inhibition constant (K<sub>i</sub>) and the concentration of inhibitor which causes 50 percent inhibitions (I<sub>50</sub>) of an enzymatic reaction. *Biochem Pharmacol*. 1973;22:3099-3108.
- [194] Tumminello FM, Bernacki RJ, Gebbia N, Leto G. Pepstatins: aspartic proteinase inhibitors having potential therapeutic applications. *Med Res Rev*. 1993;13:199-208.
- [195] Rakitzis ET. Kinetics of irreversible enzyme inhibition by an unstable inhibitor. *Biochem J*. 1974;141:601-603.
- [196] Chi CW, Lo SS, Tan FL, Zhang YS, Chu HM. Studies on the mung bean trypsin inhibitor. In: Proteins in biology and medicine, ed. Bradshaw RA, Hill RL, Tang J. Acad Press NY. 1982:341-362.
- [197] Worowski K, Gabrylewicz A, Roszkowska W, Bajko K. The action of potato inhibitors on activation of zymogen forms of digestive system proteases. *Acta Hepato-Gastroenterol*. 1979;26:413-416.
- [198] Oak MH, El Bedoui J, Anglard P, Schini-Kerth VB. Red wine polyphenolic compounds strongly inhibit pro-matrix metalloproteinase-2 expression and its activation in response to thrombin via direct inhibition of membrane type 1-matrix metalloproteinase in vascular smooth muscle cells. *Circulation*. 2004;110:1861-1867.
- [199] Daems WT, Wisse E, Brederoo P. Residual bodies and cellular defecation. In: Lysosomes a laboratory handbook, ed. Dingle JT. North-Holland Publ Comp Amsterdam-London. 1972:183-189.
- [200] Holtzman E. Lysosomes. Plenum Press NY. 1989:25-92.
- [201] Nyquist SE, Acuff K, Mollenhauer HH. Residual bodies and their components. *Biol Reproduct*. 1973;8:119-124.
- [202] Loegering DJ, Kaplan JE, Saba TM. Correlation of plasma lysosomal enzyme levels with hepatic reticuloendothelial function after trauma. *Proc Soc Exp Biol Med*. 1976;152:42-46.
- [203] Leto G, Gebbia N, Rausa L, Tumminello FM. Cathepsin D



- in the malignant progression of neoplastic diseases (review). *Anticanc Res.* 1992;12:235-248.
- [204] Leto G, Tumminello FM, Crescimanno M, Flandina C, Gebbia N. Cathepsin D expression levels in nongynecological solid tumors: Clinical and therapeutic implications. *Clin Exp Metastas.* 2004;21:91-106.
- [205] Schwartz MK. Tissue cathepsin as tumor markers. *Clin Chim Acta.* 1995;237:67-78.
- [206] Wada T, Ohara H, Watanabe K, Kinoshita H, Yachi A. Autoradiographic study on the site of uptake of the haptoglobin-hemoglobin complex. *J Reticuloendothel Soc.* 1970;8:185-193.
- [207] Loegering DJ, Carr FK, Saba TM. Cathepsin clearance from the circulation and reticuloendothelial function. *Exp Mol Pathol.* 1977;27:277-283.
- [208] Mason MS, Wangenstein SL. The effects of purified cathepsin D infusions in intact animals. *Am J Surg.* 1977;134:278-282.
- [209] de Alaniz MJT, de Gomez Dumm IN, Brenner RR. Comparative studies regarding different ways of expression of enzymatic activity. *Enzymologia.* 1970;38:85-88.
- [210] Frei J. The meaning of enzyme activity measurements in human tissues. *Enzymol Biol Clin.* 1970;11:3-7.
- [211] Fiszer-Szafarz DNA and protein content as cellular biochemical parameters. A discussion with two examples: acid phosphatase and cathepsin D in rat liver and hepatoma and acid phosphatase in human breast normal tissue and adenocarcinoma. *Anal Biochem.* 1984;138:255-258.
- [212] Khamis Ali F, Roszkowska-Jakimiec W, Gacko M, Worowska A. *Pepsin. Diag Lab.* 1995;31:595-612.
- [213] Kay J, Tatnell PJ. Cathepsin E. In: *Handbook of proteolytic enzymes*, ed. Barrett AJ, Rawling ND, Woessner JF. Elsevier Amsterdam. 2004;1:33-38.
- [214] Zaidi N, Kalbacher H. Cathepsin E: a mini review. *Biochem Biophys Res Commun.* 2008;367:517-522.
- [215] Valler MJ, Kay J, Aoyagi T, Dunn BM. The interaction of aspartic proteinases with naturally-occurring inhibitors from actinomycetes and *Ascaris lumbricoides*. *J Enzyme Inhib.* 1985;1:77-82.
- [216] Ng KKS, Petersen JFW, Cherney MM, Garen C, Zalatoris JJ, Rao-Naik C, Dunn BM, Martzen MR, Peanasky RJ, James MNG. Structural basis for the inhibition of porcine pepsin by *Ascaris* pepsin inhibitor-3. *Nat Struct Biol.* 2000;7:653-657.
- [217] Lombardo A, Caimi L, Marchesini S, Goi GC, Tettamanti G. Enzymes of lysosomal origin in human plasma and serum: assay conditions and parameters influencing the assay. *Clin Chim Acta.* 1980;108:337-346.
- [218] Leto G, Tumminello FM, Pizzolanti G, Montalto G, Soresi M, Ruggeri I, Gebbia N. Cathepsin D serum mass concentrations in patients with hepatocellular carcinoma and/or liver cirrhosis. *Eur J Clin Chem Clin Biochem.* 1996;34:555-560.
- [219] Leto G, Tumminello FM, Pizzolanti G, Montalto G, Soresi M, Carroccio A, Ippolito S, Gebbia N. Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis. *Pancreas.* 1997;14:22-27.
- [220] Molina E, Ramos M, Cifuentes A, Lopez-Fandino R. Characterization of cheese proteolysis by capillary electrophoresis and reverse-phase HPLC analyses of peptides. *Z Lebensm Unters Forsch.* 1998;206:259-263.
- [221] Shihabi ZK, Kute TE. Analysis of cathepsin D from breast tissues by capillary electrophoresis. *J. Chromat B.* 1996;683:125-131.
- [222] Chu Q, Jones S, Zeece M. Capillary electrophoretic determination of cathepsin D activity using Oregon Green-labeled hemoglobin. *Electrophoresis.* 1999;20:2945-2951.
- [223] Fu S, Chu SG, Qin ZF, Xu XB. Determination of cathepsin D activity in MCF-7 cells by capillary zone electrophoresis with on-column sample stacking. *Chromatographia.* 2003;58:73-78.
- [224] Tung CH, Bredow S, Mahmood U, Weissleder R. Preparation of a cathepsin D sensitive near-infrared fluorescence probe for imaging. *Bioconjugate Chem.* 1999;10:892-896.
- [225] Dolbear FA, Smith RE. Flow cytometric measurement of peptidases with use of 5-nitrosalicylaldehyde and 4-methoxy-b-naphthylamine derivatives. *Clin Chem.* 1977;23:1485-1491.
- [226] Rothe G, Klingel S, Assfalg-Machleidt I, Machleidt W, Zirkelbach C, Banati RB, Mangel WF, Valet G. Flow cytometric analysis of protease activities in vital cells. *Biol Chem HS.* 1992;373:547-554.
- [227] Llorente L, Richaud-Patin Y, Diaz-Borjon A, Jakez-Ocampo J, Alvarado de la Barrera C. Increased collagenase and dipeptidyl peptidase I activity in leucocytes from healthy elderly people. *Clin Exp Immunol.* 1999;116:425-429.
- [228] Llorente L, de la Fuente H, Richaud-Patin Y, Alvarado de la Barrera C, Diaz-Borjon A, Lopez-Ponce A, Lerman-Garber I, Jakez-Ocampo J. Innate immune response mechanisms in non-insulin dependent diabetes mellitus patients assessed by flow cytometry. *Immunol Lett.* 2000;74:239-244.
- [229] de la Fuente H, Richaud-Patin Y, Jakez-Ocampo J, Gonzalez-Amaro R, Llorente L. Innate immune mechanisms in the pathogenesis of systemic lupus erythematosus (SLE). *Immunol Lett.* 2001;77:175-180.
- [230] Ravdin PM, Tandon AK, Allred DC. Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. *J Clin Oncol.* 1994;12:468-474.
- [231] Schultz DC, Bazel S, Wright LM, Tucker S, Lange MK, Tachovsky T, Longo S, Alhadeff JA. Western blotting and enzymatic activity analysis of cathepsin D in breast tissue and sera of patients with breast cancer and benign breast disease and of normal controls. *Canc Res.* 1994;54:48-54.
- [232] Laury-Kleintop LD, Coronel EC, Lange MK, Tachovsky T, Longo S, Tucker S, Alhadeff JA. Western blotting and isoform analysis of cathepsin D from normal and malignant human breast cell lines. *Breast Canc Res Treat.* 1995;35:211-220.
- [233] Yokota S, Tsuji H, Kato K. Immunocytochemical localization of cathepsin D in lysosomes of cortical collecting tubule cells of the rat kidney. *J Histochem Cytochem.* 1985;33:191-200.
- [234] Mort JS, Poole AR, Decker RS. Immunofluorescent localization of cathepsin B and D in human fibroblasts. *J Histochem Cytochem.* 1981;29:649-657.
- [235] Yamato S, Hirabayashi Y, Sugihara H, Uematsu H. Electron microscopic visualization of cathepsin D using mercury-labeled pepstatin as an enzyme inhibitor. *J Histochem Cytochem.* 1982;30:1228-1234.
- [236] Goto T, Kiyoshima T, Moroi R, Tsukuba T, Nishimura Y, Himeno M, Yamamoto K, Tanaka T. Localization of cathepsins B, D, and L in the rat osteoclast by immuno-light and electron microscopy. *Histochemistry.* 1994;101:33-40.

Submitted: 3 March, 2009

Accepted after reviews: 15 June, 2009